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ABSTRACT 
 
Genetic Incorporation of Noncanonical Amino Acids into  
Proteins for Protein Function Investigation. (May 2012) 
Ying Huang, B.A., Peking University 
Chair of Advisory Committee: Dr. Wenshe Liu 
 
With the objective to functionalize proteins for the understanding of their 
biological roles and developing protein-based biosensors, I have been developing 
methods to synthesize proteins with defined modifications and applying them to study 
protein functional roles and generate proteins with new properties. These methods rely 
on the read-through of an in-frame stop codon in mRNA by a nonsense suppressor tRNA 
specifically acylated with a noncanoncial amino acid (NAA) by a unique aminoacyl-
tRNA synthetase and the genetic incorporation of this NAA at the stop codon site. NAAs 
either provide chemical handles for site-specific manipulation or mimic the 
posttranslational modifications, which are critical for understanding cellular regulations 
and signal transduction.  
The pyrrolysine synthetase (PylRS) has been wildly used to incorporate NAAs 
into proteins in E. coli. Taking advantage of PylRS, I have developed method to 
genetically incorporate ketone-containing N-ε-acetyl-L-lysine analog, 2-amino-8-
oxononanoic acid (KetoK), into proteins for their site-specific modifications and used it 
to mimic the protein lysine acetylation process.  
 iv 
I have also modified the ribosome in order to improve the amber suppression 
efficiency and therefore to achieve incorporation of multiple copies of NAA into one 
protein. By overexpressing a truncated ribosomal protein, L11C, I have demonstrated 5-
fold increase of amber suppression level in E. coli, leading to higher expression levels 
for proteins incorporated with NAAs. I have also demonstrated this method can be 
applied successfully to incorporate at least 3 NAAs into one protein in E. coli.  
With the success of incorporating multiple NAAs into one protein, I have further 
introduced two distinct NAAs into one protein simultaneously. This is done by using a 
wild type or evolved PylRS-pylTUUA pair and an evolved M. jannaschii tyrosyl-tRNA 
synthetase (MjTyrRS)-tRNACUA pair. By suppressing both UAG and UAA stop codons 
in one mRNA, a protein incorporated with two NAAs is synthesized with a decent yield.  
There is of great interest to incorporate new NAAs into proteins, which is done 
by library selection. By introducing both positive and negative selective markers into 
one plasmid, I have developed a one-plasmid selection method. In this method, the 
positive and negative selections are accomplished by in a single type of cells hosting a 
single selection plasmid. 
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1. INTRODUCTION: PYLRS, A MEDIOCRE ENZYME 
OR A GIFT FROM NATURE 
  
1.1 Introduction to protein biosynthesis 
In a cell, protein translation is the process that a nucleotide sequence in an 
mRNA is translated to be a corresponding amino acid sequence in a protein (Figure 1). 
During this process, a nucleotide triplet in an mRNA, which is called a codon, is used to 
code one amino acid. In total, there are 64 triplet codons. Shown as the standard genetic 
code for most organisms in Figure 2, 61 codons code 20 canonical amino acids and 3 
codons code for protein translation termination. To undergo protein translation, 
ribosome mediates the correct recognition of a codon in mRNA by a tRNA that is 
acylated with an amino acid by an aminoacyl-tRNA synthetase (aaRS). Acylation of a 
tRNA by an aaRS is a two-step process, the first of which is to activate amino acid by 
ATP to form aminoacyl-AMP and the second is to transfer the aminoacyl group from 
aminoacyl-AMP to the 3’ end of the tRNA.1  
1.2 Fidelity of the canonical amino acid incorporation 
Accurate acylation of tRNAs catalyzed by aaRSs is essential to keep high fidelity 
of protein translation in a cell. Typically, an aaRS consists of the ATP binding site, the 
amino acid activation site, and the tRNA binding domain. Some aaRSs have additional 
editing domains to hydrolyze the misacylated tRNAs. Based on where ATP is bound in 
____________ 
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Figure 1. Protein biosynthesis machinery. 
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Figure 2. Standard genetic code. 
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the active site, and which ribose hydroxyl group of A76 in a tRNA is acylated with an 
amino acid, aaRSs are classified into two structurally unrelated groups, namely class I 
and class II.2, 3 Two classes of aaRSs have different binding patterns when they associate 
tRNAs. A class I aaRS approaches its tRNA acceptor end from the tRNA minor groove. 
On the contrary, a class II aaRS approaches its tRNA acceptor end from the tRNA major 
groove.4 For class I aaRSs, the activated amino acids are attached to the 2' ribose 
hydroxyl group of A76. For class II aaRSs, with the exception of PheRS, the activated 
amino acids are attached at the 3' ribose hydroxyl group of A76. Among 20 regular 
aaRSs, those for methionine, valine, isoleucine, cysteine, glutamate, leucine, lysine, 
arginine, tryptophan and tyrosine belong to class I and the rest belong to class II.5 
 
 
 
 
Figure 3. Structure of Rossmann fold. PDB: 2IUE. 
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1.2.1 Class I aaRSs 
Class I aaRSs have the basic Rossmann fold, a three-layer α/β/α structure, with 
an inner core of five parallel β strands (Figure 3). In addition, two activation sites 
HXGH and KMSKS are conserved in all class I aaRSs.2 The tetrapeptide HXGH (X 
denotes a hydrophobic amino acid) is at the end of one element sequence that consists of 
11 residues; pentapeptide KMSKS is located near to the C terminus of the nucleotide-
binding domain.6 In general, due to the deep open pocket, the amino acids activated by 
class I aaRSs are usually larger than those for class II.3  
The 10 class I aaRSs are further divided into three subclasses, subclass Ia, 
subclass Ib, and subclass Ic (Table 1).7, 8 Subclass Ia contains CysRS, ArgRS, IleRS, 
LeuRS, ValRS, and MetRS. Subclass Ib contains GlnRS, GluRS, and LysRS. Subclass 
Ic includes TyrRS and TrpRS.  
 
 
Table 1. Subclasses of AaRSs 
 
 Class I Class II 
a Cys, Arg, Ile, Leu, Val, Met Ser, Pro, His, Thr 
b Gln, Glu, Lys Asp, Asn, Lys 
c Tyr, Trp Ala, Gly, Phe 
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1.2.2 Class II aaRSs 
Class II aaRSs contain a very special fold structure, with mixed α helices and β 
strands, and a core with antiparallel β strands flanked by α helices. Class II aaRSs share 
three short conserved motifs where ATP is bound and the amino acid is activated.2 
Compared to class I aaRSs, which are most monomeric, most of class II are dimeric or 
multimeric.1 
The 10 class II aaRSs are further grouped into three subclasses, subclass IIa, 
subclass IIb, and subclass IIc (Table 1).7, 8 Subclass IIa, responsible for acylation of 
small amino acids and small polar amino acids, consists of SerRS, ProRS, HisRS, and 
ThrRS. Subclass IIb aaRSs that acylate tRNAs with large polar and charged amino acids, 
include AspRS, AsnRS, and LysRS. Subclass IIc aaRSs comprise AlaRS, GlyRS, and 
PheRS.  
1.2.3 LysRS: a violator 
The classification of 20 aaRSs was thought to be generic in all species, until the 
discovery of LysRS from Methanococcus maripaludis in 1997.9 With the presence of 
characteristic Rossmann fold that are found in all class I aaRSs and absence of motives 1, 
2, and 3 that are found in a typical class II LysRS,2 M. maripaludis LysRS was classified 
as a class I aaRS (Figure 4). To date, only LysRSs have been found to exist as both class 
I and class II aaRSs. The class I LysRS is found in most archaea and some bacterial 
strains. In some archaea strains, both class I and class II LysRSs exist. Microbial genome 
sequencing discovered over 30 class I LysRSs.10 
 7 
 
 
Figure 4. Structures for class I and II LysRSs. PDB (LysRS1): 3E9I, PDB (LysRS2): 
3BJU. 
 
 
1.2.4 Indirect biosynthesis of Cys-tRNACys 
In most organisms, Cys-tRNACys is made by CysRS using cysteine.11 However, 
genomic screening showed that CysRS is absent in at least three archaea, 
Methanococcus jannaschii and Methanobacterium thermoautotrophicum and 
Methanopyrus kandleri. Since cysteine has a critical role as a nucleophilic catalyst, a 
metal ligand and an electron-carrying thiol and cysteine exists in most of proteins in 
these organisms, it is of great interest to see how cysteine is incorporated into their 
proteins. In 2002, Dr. Dieter Söll group at Yale University proposed that ProRS might be 
involved in the process of cysteine incorporation, based on the observation that ProRS 
was able to form Cys-tRNAPro using cysteine as the substrate.12 Nevertheless, 
contradicting data were reported later. By using acid urea gel electrophoresis analysis, it 
was shown that ProRS isolated from M jannaschii was unable to acylate mature tRNACys 
purified from M. jannaschii.13 The discovery of a novel enzyme MJ1660 from the 
 8 
bioinformatic analysis solved the puzzle.14 MJ1660, found in M. jannaschii, was able to 
catalyze the ligation between a phosphoserine (Sep) (Figure 5) and tRNACys. MJ1660, 
later named as phosphoseryl-tRNA synthetase (SepRS), might play an equivalent role as 
CysRS.15 Different from a classical class I CysRS, SepRS is a typical class II aaRS.15 
The biosynthesis of Cys-tRNACys is started from the synthesis of Sep-tRNACys and 
completed by another novel enzyme, MJ1678. MJ1678, a Sep-tRNA:Cys-tRNA 
synthetase (SepCysS), further converts Sep-tRNACys to Cys-tRNACys, using pyridoxal 
5’-phosphate (PLP) as a cofactor.15 Therefore, a new route for the biosynthesis of Cys-
tRNACys was demonstrated (Figure 5). In addition, this pathway serves as the only 
pathway in Methanococcus maripaludis to synthesize Cys-tRNACys.15 The SepRS is a 
unique synthetase that involves in the biosynthesis of a NAA, Sep. 
 
 
 
 
Figure 5. Indirect biosynthetic route of Cys-tRNACys. 
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1.2.5 Indirect biosynthesis of Gln-tRNAGln 
GlnRS was first found to be absent in the Bacillus subtilis in the late 1960’s.16 
After extensive studies, GlnRS turns out to be rare, only found in eukaryotes and a few 
bacteria.1, 17 Since all archaea and most of bacteria are lack of GlnRS, Gln-tRNAGln is 
synthesized by an indirect pathway (Figure 6).18, 19 This alternative pathway requires two 
kinds of enzymes. One kind of enzymes is non-discriminating GluRS (ND-GluRS) that 
acylates both tRNAGlu and tRNAGln with glutamate or misacylating GluRS (GluRS2) that 
only acylates tRNAGln with glutamate,20, 21 the other one is glutamine dependent Glu-
tRNAGln amidotransferase (Glu-Adt) or glutamine dependent Asp-tRNAAsn/Glu-tRNAGln 
amidotransferase (Asp/Glu-Adt).22 Glu-Adt and Asp/Glu-Adt use glutamine as the 
primary nitrogen source to convert Glu-tRNAGln to Gln-tRNAGln. The universal absence 
of GlnRS and presence of Glu-Adt in all known archaea genomes indicates it might be 
the only Gln-tRNAGln synthesis pathway. 
 
 
 
 
Figure 6. Indirect Gln-tRNAGln synthesis pathway. 
+ tRNAGln
ND-GluRS
or GluRS2
+H3N
O-
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There are two kinds of GluRSs, ND-GluRS and discriminating GluRS (D-
GluRS).10 Species with functional GlnRS such as eukaryotes contain only D-GluRS that 
generates Glu-tRNAGlu. In all archaea and most bacteria, only ND-GluRS exists. ND-
GluRS has a relaxed binding specificity toward tRNAs and binds both tRNAGlu and 
tRNAGln.23, 24 ND-GluRS has a larger anticodon binding site than D-GluRS that 
accommodates both C36 of tRNAGlu and G36 of tRNAGln.25 ND-GlnRS mediates the 
misacylation of tRNAGln with glutamate to form Glu-tRNAGln that undergoes a 
transamidation reaction to form Gln-tRNAGln. This transamidation reaction is an ATP 
dependent process. ATP is used to activate the carboxyl group to form an acyl 
phosphate. An ammonia molecule provided by hydrolysis of glutamine or asparagine 
then undergoes an SN2 reaction with the acyl phosphate intermediate to form the final 
product Gln-tRNAGln (Figure 7). In archaea, these reactions are carried out by Glu-Adt, a 
heterodimer composed of the GatD and GatE subunits, using glutamine as the nitrogen 
source.26 On the contrary, in bacteria, organelles of some eukaryotes, and some archaea, 
these reactions are catalyzed by the Asp/Glu-Adt, a heterotrimer composed of the GatC, 
GatA, and GatB.26, 27 In some special organisms, both Glu-Adt and Asp/Glu-Adt exist.26 
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Figure 7. Transamidation reaction. 
 
 
1.2.6 Indirect biosynthesis of Asn-tRNAAsn 
Similar as the indirect biosynthesis of Gln-tRNAGln, in some organisms that lack 
AsnRS, Asp-tRNAAsn is generated by misacylation of tRNAAsn with aspartate followed 
by the conversion of Asp-tRNAAsn to Asn-tRNAAsn.28, 29 The misacylation reaction is 
catalyzed by a non-discriminating AspRS (ND-AspRS). The transamidation reaction is 
accomplished by Asp/Glu-Adt (Figure 8). Although analogous to each other, there are 
some unique features in the biosynthesis of Asn-tRNAAsn. Unlike the universal absence 
of GlnRS in archaea, not all archaea are lack of AsnRS. Therefore, there is only one 
indirect pathway to generate Gln-tRNAGln, while both direct and indirect pathways to 
produce Asn-tRNAAsn exist in archaea.30 In addition, there is only one enzyme that 
catalyzes the transamidation reaction of Asp-tRNAAsn to Asn-tRNAAsn, as Asp-tRNAAsn 
is not a substrate for Glu-Adt.31 32 
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Figure 8. Indirect synthetic pathway of Asn-tRNAAsn. 
 
 
1.3 The genetic incorporation of NAAs in nature 
Proteins are the most important players within a cell by carrying out reactions in 
most of cellular processes such as DNA replication, transcription, translation, 
metabolism, signal transduction, etc.33 The diversity of protein functions arises from 
three aspects of their structures: primary amino acid sequence, post-translational 
modification, and protein folding.  
Generally speaking, the genetic code of all known organisms specifies the same 
20 canonical amino acids. NAAs are amino acids with additional functions groups 
beyond what 20 canonical amino acids could provide. It is clear that many proteins 
require additional chemical groups to carry out their native functions. Nature satisfies 
this requirement by one process that is called posttranslational modifications. Many of 
functional groups are installed into proteins through covalent posttranslational 
modifications of amino acid side chains, including acetylation, methylation, 
phosphorylation, sulfation, glycosylation, lipidation, etc. (Figure 9).34 These 
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modifications, to a great extent, grant proteins with expanded opportunities for catalysis, 
mediating signal transduction, and alteration of cellular locations.  
There are more than 140 kinds of amino acids that have been found in natural 
proteins, most of which are due to the posttranslation modification process. However, 
two other NAAs selenocysteine and pyrrolysine are incorporated into protein 
cotranslationally (Figure 10). Selenocysteine, the 21st amino acid, was first found in a 
subunit of Clostridium stricklandii glycine reductase in 1976.35 Pyrrolysine, the 22nd 
amino acid, was discovered in methylamine methyltransferase in Methanosarcina 
barkeri in 2002.36, 37 
1.3.1 Biosynthesis of selenocysteine 
Selenium, a trace element required for mammals, serves as pivotal catalytic roles 
in many enzymes. Selenium carries out its functions in proteins as a form of 
selenocysteine.35 Compared with cysteine that has a pKa close to 8.5, selenocysteine 
with a pKa of 5.2 exists as a selenolate anion form at physiological pH.38 In addition, the 
selenol group of selenocysteine is more redox sensitive and higher nucleophilic than the 
thiol group of cysteine. Indeed, most known selenoproteins are oxidoreductases with an 
essential selenocysteine active site residue. Mutation of selenocysteine in the active sites 
of these enzymes to cysteine causes more than 100-fold decrease in their catalytic 
turnover.38  
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Figure 9. Representative post-translation modifications. 
 
 
 
 
Figure 10. Structures of selenocysteine and pyrrolysine. 
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After its initial identification in a subunit of Clostridium stricklandii glycine 
reductase in 1976,35 it took ten years to further demonstrated that selenocysteine is 
directed incorporated into proteins by an in-frame UGA opal stop codon.39, 40 Because it 
is genetically encoded, selenocysteine has been named as the 21st amino acid. It is now 
well accepted that selenocysteine has been used in all three domains of life, but not in all 
species. Although there are more than 30 selenocysteine-containing proteins in 
mammalian cells, selenocysteine is not genetically encoded from fungi and higher 
plants.41, 42 To date, the biosynthesis pathway of selenocysteine-containing proteins has 
been elucidated that selenocysteine is incorporated into protein via selenocysteinyl-
tRNASec (Sec-tRNASec). 
1.3.1.1 The biosynthesis of selenocysteine-containing proteins in bacteria  
The biosynthesis of Sec-tRNASec in bacteria follows an indirect pathway, similar 
as the indirect pathway of Gln-tRNAGln. There are two steps involved, the acylation of 
tRNASec (SelC) by SerRS to generate Ser-tRNASec and the following conversion from 
Ser-tRNASec to Sec-tRNASec (Figure 11).43 The conversion from Ser-tRNASec to Sec-
tRNASec is catalyzed by the enzyme selenocysteine synthase (SelA), a PLP-dependent 
enzyme, using selenophosphate, which is made by selenophosphate synthase (SelD) 
from selenide and phosphate, as the selenium donor.44 Later, the synthesized Sec-
tRNASec is incorporated into a protein at an opal UAG codon with the help of a Sec-
tRNASec specific elongation factor (SelB) since the endogenous elongation could not 
recognize Sec-tRNASec.45 The site-specificity is control by a special hairpin loop element 
structure that is called selenocysteine insertion sequence (SECIS) in the encoding 
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mRNA. In bacteria, the SECIS hairpin is located immediately downstream from the in-
frame UGA opal stop codon.46 
 
 
 
 
Figure 11. Indirect Sec-tRNASec synthetic pathway in bacteria. 
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to Sec-tRNASec by SepSecS, a PLP dependent enzyme (Figure 12).47, 48 Different from 
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elongation factor (EFSec) and a unique SECIS-binding protein (SBP2) need to form a 
complex to mediate the binding of SECIS with Sec-tRNASec for the correct recognition 
of an opal codon in mRNA.50 
The incorporation of selenocysteine into proteins in archaea is the combination of 
those in bacteria and eukaryotes. The biosynthesis of Sec-tRNASec is as same as the 
+ tRNASec
SerRS
+H3N
O-
O
OH
ATP AMP + PPi
+H3N
O-tRNASec
O
OH SelA +PLP
+H3N
O-tRNASec
O
SeH
O
P-O Se-O-
 17 
pathway in mammals,48 and the SECIS motif is far away from opal stop codon. 
However, only SelB is required to associate Sec-tRNASec with SECIS for the correct 
recognition of an mRNA opal codon.51  
1.3.2 Biosynthesis of pyrrolysine 
In 1998, Krzycki et al. reported that there is a traditional UAG amber stop codon 
in the open reading frame of monomethylamine methyltransferase (MtmB) in 
Methanosarcina barkeri.36 The crystal structure of MtmB clearly indicated the presence 
of a lysine analog at this amber codon site that was later confirmed to be pyrrolysine.37, 
52 MtmB is a critical enzyme in Methanosarcinaceae.37 Methanosarcinaceae are a group 
of methanogenic archaea that are able to reduce a wide variety of compounds to methane. 
Methanosarcinaceae are special for that they produce methane from methylamines 
(mono-, di-, and trimethylamines). This process requires specific methyltransferases, 
such as monomethylamine methyltransferase (mtmB), dimethylamine methyltransferase 
(mtbB), or trimethylamine methyltransferase (mttB).53 The genes of MttB, MtbB, and 
MtmB contain a single in-frame amber codon.54, 55 Based on the fact that pyrrolysine 
was observed in the crystal structure to bind ammonia,52 the mechanism of 
methyltransferation is proposed in Figure 13.56 MttC, MtbC, and MtmC are cognate 
corrinoid proteins, which involve in the conversion of the methyl group to carbon 
dioxide.57, 58  
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Figure 12. Indirect Sec-tRNASec synthetic pathway in eukaryotes. 
 
 
 
 
Figure 13. Monomethylamine metabolism in Methanosarcinaceae. 
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1.3.3 The cotranslational incorporation of pyrrolysine 
Efforts were made to elucidate how pyrrolysine was cotranslationally inserted 
into proteins after its discovery. Bioinformatic analysis of the Methanosarcina barkeri 
genome revealed a pyl gene cluster that contains pylT, pylS, pylB, pylC, and pylD 
(Figure 14).59 pylT codes a special tRNA, tRNAPyl that has a CUA anticodon and pylS 
codes a putative class II aminoacyl-tRNA synthetase.37 PylB, pylC and pylD have 
putative functions in the biosynthesis of pyrrolysine. To date, there are six bacterial and 
six archaeal species found with similar pyl gene clusters.  
After pylT was identified, two possible routes for the biosynthesis of pyrrolysine-
containing proteins were proposed. PylS might acylate pylT with pyrrolysine for its 
direct incorporation at an amber codon or lysine is first linked to pylT either by pylS or 
another aaRS, followed by further modification to generate pyrrolysyl (Pyl)-tRNAPyl.  
Originally, it was uncovered that both class I and class II LysRSs in M. barkeri were 
required to form lysyl-tRNAPyl, indicating the indirect synthesis route to Pyl-tRNAPyl, 
like the 21st amino acid selenocysteine.60 It is worth noting that pylS itself could not 
ligate lysine to pylT. However, later in 2004,61 Krzycki group demonstrated that 
pyrrolysine is attached as a free molecule to pylT by pylS in vitro. This is the first 
example of direct aminoacylation of a tRNA with a NAA, earlier than SepRS. The idea 
was further confirmed by the fact that the pair of pylS and pylT was moved to E. coli for 
the genetic incorporation of NAAs at amber mutation sites. Unlike sec-tRNASec, Pyl-
tRNAPyl could be recognized by endogenous elongation factor, EF-Tu.62 The mechanism 
of the genetic incorporation of pyrrolysine is shown in Figure 15.59 
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Figure 14. Pyl gene cluster. 
 
 
1.3.4 The introduction to pylS 
PylRS coded by pylS is an archaeal class II aaRS.61 Since PylRS has been found 
in different organisms, the crystal structures of several PylRS variants in archaea, such 
as Methanosarcina mazei (MmPylRS),63 and bacteria D. hafniense (DhPylRS) has been 
solved (Figure16).64-66 MmPylRS has two major domains, the structurally unresolved N-
terminal domain, and the catalytic C-terminal domain.63 However, DhPylRS only 
contains the catalytic domain. The N-terminal domain equivalent is coded by a different 
gene that is called pylSn.66 With classic β-sheet core and three special motifs, PylRS is a 
class II aaRS. As a matter of fact, PylRS belongs to subclass IIc, together with AlaRS, 
SepRS, and PheRS. Subclass IIc aaRSs all have a similar core domain. In addition, all of 
them could potentially form quaternary complexes.63 Actually, phylogenetic tree 
suggests that they may evolve from a same ancestor aaRS.  
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Figure 15. Incorporation of pyrrolysine. 
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Another question about aaRS is whether a similar mRNA secondary structure 
like SECIS is required for the incorporation of pyrrolysine, just like selenocysteine. 
There are some data showed that the cis-element PYLIS enhanced the suppression level 
of pyrrolysine incorporation in E. coli.67 Since there is no particular motif for PylRS to 
discriminate TAG as an in-frame sense codon or stop codon, how could pyrrolysine-
containing species function normally? Indeed, pyrrolysine-containing species have 
shown a low occurrence frequency of this stop codon.29 
 
 
 
 
Figure 16. Crystal structure of DhPylRS with pylT. 
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1.3.5 The introduction to pylT 
The DNA sequences of pylT differ a lot. PylT variants from archaeal share 87% 
sequence identity, while pylT variants from bacteria only share 45% sequence identity. 
In spite of very diversified DNA sequences, all pylT homologs have same unusual 
secondary structures (Figure 17), including a three-base variable loop (not 4 bases), 
small D-loop, long anticodon stem (six nucleotide pairs instead five), and a single base 
between the D-stem and acceptor stem (not 2 bases).59, 64  
 
 
 
 
Figure 17. Structure of MmpylT. 
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1.3.6 The biosynthesis of pyrrolysine 
Like all other 20 amino acids, pyrrolysine should first be synthesized and then be 
incorporated into proteins. Thus, there leaves another question about the biosynthesis of 
pyrrolysine. It has been demonstrated that transferring the whole pyl gene cassette into 
E. coli led to the suppression of amber mutations. Besides pylT and pylS, the same 
pylBCD arrangement has been maintained in all pyrrolysine-containing species.59 The 
remaining pylBCD genes in the pyl gene cluster are expected to involve in the enzymatic 
pathway of biosynthesis of pyrrolysine.68 Protein sequence alignment provided clues for 
the functions of pylBCD. PylB has typical structure of SAM family. PylC belongs to the 
ligase family. pylD has the feature of dehydrogenases.69 
At the beginning, one lysine and other metabolic products, such as ornithine61 
were proposed to be the precursors of the pathway. Recently, Krzycki and his colleagues 
have demonstrated only lysine is the precursor. The route for the conversion of two 
lysines to pyrrolysine has been elucidated using stable isotope labeling and mass 
spectrometry (Figure 18).70 The SAM-dependent protein pylB conducts the conversion 
of a lysine to 3-methylornithine, followed by a ligation reaction with another lysine by 
pylC. After the oxidation reaction carried out by pylD, pyrrolysine is formed by the 
spontaneous elimination of H2O. 
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Figure 18. Biosynthetic route for pyrrolysine. 
 
 
1.4 PylRS: a mediocre enzyme 
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From the evolution history, bacteria first separated from the other two, and then the 
remaining life has divided into archaea and eukaryotes. Thus, the tRNA/codon/aaRS sets 
in the bacteria are possibly orthogonal to the pairs in the archaea and eukaryotes. The 
tRNA/codon/aaRS sets in the archaea and eukaryotes may crosstalk to each other.  It is 
very hard to find one aaRS-tRNA pair that is both orthogonal in bacteria and eukaryotes, 
two systems we use a lot for the genetic code expansion. Therefore, the orthogonality of 
the PylRS-tRNA pair in both bacteria and eukaryotes makes it an optimal choice because 
the pair can be easily evolved in bacteria and then transfer to other domains of life. This 
special orthogonality of the PylRS-pylT pair basically in three domains of life might be 
due to the fact that PylRS appeared before the division of life.63 
1.4.2 The deep hydrophobic binding pocket of PylRS 
Due to the large size of pyrrolysine, the amino acid active site of PylRS has a 
very deep hydrophobic binding pocket (Leu305, Tyr306, Leu309, Cys348, and Tyr384) 
to sandwich the pyrrole group of pyrrolysine.63 The phenolic hydroxyl group of Tyr384 
forms a hydrogen bond with nitrogen of the pyrrole ring. However, there is no hydrogen 
bond with ε-amino group (Figure 19). 
Given that there is only one hydrogen bond involving in the binding of 
pyrrolysine and no other natural amino acids could be taken by PylRS, the specific 
interaction between PylRS and pyrrolysine is mediated by van der Waals or hydrophobic 
interactions between the binding pocket and the pyrrole group. In comparison to the size 
of the pyrrole group, the binding pocket is exceptionally large, which clearly indicates 
the binding site may fit other large NAAs that contain hydrophobic side chains. The lack 
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of an editing domain will allow misacylated tRNAPyl to leave PylRS and deliver the 
linked NAA to ribosome for its incorporation at an amber mutation site. 
 
 
 
 
Figure 19. Binding pocket of MmPylRS with Pyl-AMP. 
 
 
 An editing domain is very important to maintain translation fidelity. The 
charging of the tRNA with its cognate amino acid is critical for the accurate translation. 
An aaRS needs to specifically acylate its tRNA with its cognate amino acid, but against 
structurally similar amino acids. The existence of an editing domain solves this problem. 
Taking IleRS for example, valine differs from isoleucine only by the lack of a single 
methyl group. Surprisingly, IleRS, with an editing domain, transfer 40000 or so 
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isoleucine molecules to tRNAIle for every valine it can transfer (Figure 20).71, 72 However, 
there is no editing domain in the PylRS, making the use of PylRS to charge pylT with 
NAAs possible. 
 
 
 
 
Figure 20. Editing domain of IleRS. 
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1.4.3 The weak interaction between α-amino group of pyrrolysine and PylRS 
According to the PylRS crystal structure, there are two significant residues. One 
is the Tyr384 mentioned above, and the other one is Asn346. Asn346 is important for 
binding of pyrrolysine to the active site at two aspects. Asn346 forms hydrogen bonds to 
both the side chain amide oxygen of pyrrolysine and a water molecule that also forms a 
hydrogen bond with the α-amino group of pyrrolysine (Figure 21).63 PylRS is the only 
known aaRS that does not have any direct interaction with the α-amino group of its 
cognate amino acid. The α-amino group of pyrrolysine is not involved in direct 
interactions with residues of PylRS. This makes it possible for PylRS to recognize α-
hydroxyl acid derivative. The possible reason for PylRS not to specifically recognize 
pyrrolysine could be due to the fact that there is no similar hydroxyl acid existing in cells 
and the specific recognition of the α-amino group may increase the binding of the ligand 
to an extent that other natural amino acid could be recognized by the enzyme.   
1.4.4 The lack of stringent interactions between the pylT anticodon and PylRS 
As an aaRS, PylRS interacts with both pyrrolysine and pylT. Dieter Söll group 
demonstrated the high conservation of the interaction between pylT and PylRS.64 There 
is 54% sequence identity for pylT binding regions of PylRS from different origins, 
compared with only 39% sequence identity for the whole protein.64 The binding of pylT 
by PylRS relies on a combination of direct interactions with certain nucleotides of pylT 
and recognition of the overall tertiary structure of pylT.64 Detailed studies of the 
interactions uncovered the pylT major identity elements, including the discriminator 
base G73 and the first base pair of the acceptor stem.73 The mutation at D-loop, T-loop 
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and variable stem also showed the decreasing binding of pylT to PylRS,73 while no 
direct interaction between these regions of pylT with PylRS. These data further 
confirmed the idea that the recognition of pylT is a combination of the specific binding 
of identity elements and the association of overall structure of pylT to PylRS.  
 
 
 
 
Figure 21. Water-mediated binding of α-amino group. 
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ancestor of several other aaRSs. The lack of the interactions with pylT anticodon might 
make the primitive aaRS easily evolve to other aaRSs, such as PheRS. 
1.5 PylRS: a gift from nature 
With few exceptions, the genetic code of all known organisms specifies the same 
20 canonical amino acid building blocks. However, it is clear that many proteins require 
additional chemical groups beyond what the 20 building blocks can provide to carry out 
their native functions.34 Many of these groups are installed into proteins through 
covalent posttranslational modifications of amino acid side chains, including acetylation, 
methylation, phosphorylation, sulfation, etc. These modifications, to a great extent, 
expand the amino acid inventory of proteins by assimilating NAAs and grant proteins 
expanded opportunities for catalysis, mediating signal transduction, integration of 
information at many metabolic intersections, and alteration of cellular locations. 
A major challenge in studying posttranslationally modified proteins is that they 
exist typically as a mixture of different forms. This makes it difficult to purify uniquely 
modified forms from their natural sources. For this reason, a variety of approaches have 
been developed to synthesize proteins with defined posttranslational modifications that 
can be easily isolated. One of these approaches uses the nucleophilicity of cysteine to 
incorporate NAAs into proteins.74 Native chemical ligation and its extension, expression 
protein ligation, have also been used to install NAAs into proteins.75 These two 
approaches provide great opportunities to study functional roles of posttranslational 
modifications. However, they both are in vitro semisynthetic techniques and cannot been 
applied in vivo. An alternative NAA installation approach that can be carried out in vivo 
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is the genetic incorporation of NAAs directly into proteins during translation in living 
cells. 
1.5.1 Introduction of genetic incorporation of NAAs 
The method of genetic incorporation of NAAs in live cells has been developed 
by Schultz et al.76-82 This method relies on the read-through of an in-frame amber (UAG) 
stop codon in mRNA by an amber suppressor tRNA (tRNACUA) specifically acylated 
with a NAA by an evolved aaRS. An orthogonal aaRS-tRNACUA pair can be developed 
to specifically charge its cognate tRNACUA with a NAA. When expressed in cells, this 
aaRS-tRNACUA pair enables the NAA to be site-specifically incorporated into a protein.  
Several aaRSs have been applied for genetic incorporation of NAAs, such as 
TyrRS from E. coli83 and Methanococcus jannaschii,84 TrpRS from E. coli,84 PheRS 
from S. cerevisiae,85 LysRS,84 and LeuRS from E. coli.84 Among all the available aaRSs, 
TyrRS from M. jannaschii is the most used one for the genetic code expansion, for more 
than 50 NAAs have been incorporated into proteins by evolved MjTyrRS.86   
1.5.2 The unique orthogonality of PylRS  
The introduction of aaRS-tRNACUA into a new system has one prerequisite, the 
orthogonality. As mentioned above, the aaRS-tRNACUA sets in the bacteria are possibly 
orthogonal to the pairs in the archaea and eukaryotes. The aaRS-tRNACUA sets in the 
archaea and eukaryotes may crosstalk to each other. Thus, the aaRSs from archaea have 
been introduced into E. coli, while not eukaryotes. On the contrary, the aaRSs from E. 
coli are used to expand the genetic codon in eukaryotes. The incompatibility of using 
one aaRS-tRNACUA pair in different organisms such as in both E. coli and eukaryotes 
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has greatly hindered the genetic code expansion for the NAA incorporation in these 
organisms.   
For above reasons, the discovery that PylRS-pylT pair is orthogonal to both E. 
coli and eukaryotes, makes it a very attractive genetic code expanding tool. As a matter 
of fact, ever since Yokoyama group first put the pyrrolysine analogs into mammalian 
cells in 2008,87 many NAAs have been incorporated into proteins in eukaryotes by 
evolving the PylRS-pylT pair in E. coli and then transferred to eukaryotic cells such as 
yeast and mammalian cells.86, 88, 89 
1.5.3 The deep hydrophobic binding pocket  
The evolution of aaRS mutants to specifically recognize one NAA begins with 
the generation of a library in the active site. The residues around the active site have 
been randomLy mutated to generate the library to take other amino acids. However, the 
variety of the amino acids it could take largely depends on the original size of the active 
site. Taking TyrRSs for example, the mutants mainly take phenylalanine and tyrosine 
derivatives, and some other NAAs with short side chains. 
 The deep pocket of PylRS offers a great opportunity to introduce the NAAs with 
long side chains. Indeed, many lysine analogs have been incorporated into proteins by 
PylRS or its mutants (Figure 22). In addition, phenylalanine and tyrosine analogs have 
also been reported to be taken by PylRS.90 Therefore, the large pocket provides the 
diversity of NAAs.  
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1.5.4 The lack of strong interactions between PylRS and pyrrolysine α-amino group  
PylRS is the only known aaRS that interacts with the α-amino group of the 
substrate indirectly through a water molecule. The lack of strong interactions grants a 
chance of incorporating non-α-amino substrates. It’s of our knowledge that the backbone 
of proteins is consisted of the amide bond. The possibility of introducing non-α-amino 
acids into proteins is expected to expand the backbone diversity of proteins. Yokoyama 
et al. reported the successful incorporation of one non-α-amino acid: α-hydroxyl acid 
(Figure 23). 
 
 
 
 
Figure 22. Representative NAAs taken by wild type and evolved PylRSs. 
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Figure 23. Non-α-amino acid incorporated into proteins. 
 
 
1.5.5 The lack of specific interactions between PylRS and pylT anticodon  
The amber stop codon is the primarily used codon for codon expansion in vivo 
due to the specific interactions between most aaRSs used for genetic code expansion and 
their cognate tRNAs. It’s not the case for PylRS. Without the concern of specific 
interactions with PylRS, the anticodon can theoretically be mutated to any codon, which 
greatly promotes the codon expansion. The introduction of other codons is extremely 
critical for simultaneous translational incorporation of two different NAAs into a single 
protein. In addition, different codons could be tested for optimized suppression in 
different systems.  
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2. GENETICALLY ENCODING KETOK INTO ONE  
PROTEIN IN ESCHERICHIA COLI* 
 
2.1 Introduction 
The keto group is one of the most versatile functional groups in organic 
chemistry due to its high reactivity with hydrazide, and hydroxylamino-bearing 
compounds under physiological conditions.91 This unique feature has been widely used, 
such as biopolymer modification (Figure 24).92 Due to the usually absence from 
proteins, a variety of approaches have been developed to achieve the of the keto or 
aldehyde group into proteins. For instance, an N-terminal serine could be transferred to 
aldehyde group in the presence of periodates.93 The keto group has also been obtained by 
enzymatic modifications of specific tags that are genetically linked to proteins and 
utilized to site-specifically label proteins on cell surface.94-96 Although both chemical 
and enzymatic methodologies provide ways for installation of keto group, the site of 
installation has been limited to the two termini of protein. Given the above fact, site-
specific incorporation of NAAs by an orthogonal aaRS/tRNA pair is an alternative 
powerful approach to selectively install keto group at any desired site of a protein.  
After the genetic incorporation of p-acetyl-phenylalanine (p-Ac-Phe) into 
proteins in E. coli,97 several more phenylalanine derivatives bearing ketone group have  
 
*Reprinted with permission from “Genetic Incorporation of an Aliphatic Keto-
Containing Amino Acid into Proteins for Their Site-Specific Modifications” by Huang, 
Y., Wan, W., Russell, W. K., Pai, P. J., Wang, Z., Russell, D. H., Liu, W., 2010. Bioorg. 
Med. Chem. Lett., 20, 878-880, Copyright [2010] by Elsevier. 
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been reported to be successfully incorporated into proteins.98, 99 However, besides the 
potential protein misfolding problem caused by the introduction of bulky aromatic ring, 
the aromatic ring decreases the activity of ketone group, for no significant reaction could 
occur under physiological conditions. Thus, it’s desirable to incorporate an aliphatic 
keto-containing amino acid into protein to gain high reactivity. 
 
 
 
 
Figure 24. Reaction of the keto group in biopolymers. 
 
 
Recently, Chin group demonstrated that the evolved MbPylRS 
(AcKRS)/tRNACUA pair can be directly used to incorporate acetyllysine (AcK) into 
proteins.100 Since the N-ε-amide NH group of AcK is not involved in any apparent 
hydrogen bonding interactions with vicinal residues of AcKRS when bound to the active 
site,63 we reasoned that changing the amino acid substrate from AcK to KetoK should 
not significantly affect the substrate’s binding potential to AcKRS. Herein, I proposed to 
 38 
use the AcKRS/pylT pair to genetically incorporate KetoK into proteins in E. coli. Our 
interest of KetoK is due to the chemical activity of aliphatic keto group, and it is an 
unhydrolysable mimic of AcK. 
2.2 Experiments and results 
2.2.1 The synthesis of 2-amino-8-oxononanoic acid (KetoK) 
Starting from 6-bromohexanoic acid, racemic KetoK was conveniently 
synthesized in gram quantities over a 6-step sequence in 50% overall yield (Scheme 1). 
 
 
Scheme 1. Synthesis of KetoK 
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2.2.1.1 7-Bromoheptan-2-one101  
A modified literature procedure101 was employed. A mixture of 1 (2.73 g, 14.0 
mmol), 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (3.22 g, 16.8 
mmol), 4-dimethylaminopyridine (0.17 g, 1.4 mmol), and N,O-dimethylhydroxylamine 
(1.5 g, 15.4 mmol) in dichloromethane (75 mL) was stirred at room temperature for 16 h. 
The mixture was diluted in dichloromethane (100 mL), washed with water (30 mL), 
hydrochloric acid (0.5 N, 30 mL), sodium hydroxide (0.5 N, 30 mL) and brine (15 mL), 
dried (Na2SO4), and concentrated under reduced pressure to give the crude 6-bromo-N-
methoxy-N-methylhexanamide (3.39 g, quant.) as yellow oil. The material was directly 
used without further purification. 
 To a stirred solution of the above amide (3.39 g, ~14.0 mmol) in anhydrous THF 
(40 mL) cooled in an ice bath under argon protection was added a solution of 
methylmagnesium bromide (3.0 M in diethyl ether, 7.4 mL, 22.2 mmol) dropwise over 
20 min. After stirring for 3 h, hydrochloric acid (1.0 N, 21.9 mL) was cautiously added 
dropwise. The mixture was diluted in ethyl acetate (50 mL), washed with water (20 mL) 
and brine (20 mL), dried (Na2SO4), and concentrated under reduced pressure to give 
crude 2 (2.35 g, 83%) as yellow oil, which was directly used in the next step. 1H NMR 
(300 MHz, CDCl3) δ 3.41 (2 H, t, J = 6.9 Hz), 2.46 (2 H, t, J = 7.2 Hz), 2.15 (3 H, s), 
1.88 (2 H, appar. quintet, J = 6.9 Hz), 1.65-1.54 (2 H, m), 1.49-1.37 (2 H, m) (Figure 
25). 
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Figure 25. 1H NMR spectrum for compound 2. 
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2.2.1.2 7-Iodoheptan-2-one101 
A literature procedure101 was followed. A mixture of 2 (2.35 g, 12.1 mmol) and 
sodium iodide (5.47 g, 36.4 mmol) in acetone (40 mL) was refluxed for 5 h. The solvent 
was then evaporated under reduced pressure and ether (50 mL) was added. The 
suspension was filtered and washed with ether (20 mL). The combined filtrate was 
washed with water (15 mL), sodium thiosulfate (1.0 M, 10 mL) and brine (10 mL), dried 
(Na2SO4), and concentrated under reduced pressure to give 3 (2.90 g, 95%) as yellow 
oil, which was directly used in the next step. 1H NMR (300 MHz, CDCl3) δ 3.19 (2 H, t, 
J = 6.9 Hz), 2.46 (2 H, t, J = 7.2 Hz), 2.15 (3 H, s), 1.86 (2 H, appar. quintet, J = 6.9 Hz), 
1.60 (2 H, appar. quintet, J =7.5), 1.45-1.32 (2 H, m) (Figure 26). 
 
 
 
 
Figure 26. 1H NMR spectrum for compound 3.	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2.2.1.3 2-(5-Iodopentyl)-2-methyl-1,3-dioxolane101 
 A literature procedure101 was followed. A mixture of 3 (3.33 g, 13.2 mmol), 
ethylene glycol (4.09 g, 66 mmol), and p-toluenesulfonic acid (0.75 g, 3. 96 mmol) in 
toluene (60 mL) was heated at reflux for 48 h, during which time the generated water 
was removed by a Dean-Stark apparatus. The reaction was monitored by TLC. Most of 
the solvent was removed through the Dean-Stark apparatus, and the residue was 
redissolved of ethyl acetate (60 mL), washed with sodium hydroxide (0.5 N, 20 mL) and 
brine (15 mL), dried (Na2SO4), concentrated, and chromatographed (ethyl 
acetate/hexanes, 1:9) to give 4 (3.35 g, 89%) as yellow oil. 1H NMR (300 MHz, CDCl3) 
δ 4.00-3.83 (4 H, m), 3.20 (2 H, t, J = 7.2 Hz), 2.46 (2 H, t, J = 7.5 Hz), 2.15 (3 H, s), 
1.90-1.79 (2 H, m), 1.70-1.54 (2 H, m), 1.50-1.36 (2 H, m) (Figure 27). 
 
 
 
 
Figure 27. 1H NMR spectrum for compound 4. 
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2.2.1.4 Diethyl 2-acetamido-2-(5-(2-methyl-1,3-dioxolan-2-yl)pentyl) malonate 
 To a suspension of diethylacetamidomalonate (0.70 g, 3.60 mmol) in anhydrous 
DMF (2 mL) was added sodium hydride (60% dispersion in mineral oil, 0.15 g, 3.84 
mmol), and the mixture was stirred at room temperature for 10 min.  Compound 4 (1.00 
g, 3.52 mmol) in DMF (2 mL) was then added dropwise over 5 min, and the resulting 
yellow solution was stirred at room temperature overnight. Water (1 mL) was added, and 
the mixture was diluted in ethyl ether (50 mL), washed with a mixture of brine (9 mL) 
and hydrochloric acid (1 N, 1 mL), dried (Na2SO4), concentrated under reduced pressure, 
and chromatographed (ethyl acetate/hexanes, 1:3 to 1:1) to give 5 (0.98 g, 82%) as 
yellow oil. 1H NMR (300 MHz, CDCl3) δ 4.631 (4 H, t, J = 7.2 Hz), 4.36-4.26 (4 H, m), 
2.70 (2 H, appar. t, J = 8.7 Hz), 2.42 (3 H, s), 2.10-1.96 (2 H, m), 1.80-1.65 (4 H, m), 
1.68-1.60 (9 H, m), 1.56-1.42 (2 H, m) (Figure 28). 
 
 
 
 
Figure 28. 1H NMR spectrum for compound 5. 
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2.2.1.5 2-Amino-8-oxononanoic acid hydrochloride 
A suspension of 5 (3.63 g) in concentrated hydrochloric acid (12 N, 20 mL) was 
heated at refluxed overnight. The solvent was evaporated under a high vacuum generated 
by an oil pump, and the residue was dissolved in minimal amount of water and loaded 
onto an ion-exchange column made from Dowex 50WX4-400 cation-exchange resin 
(wet volume ~10 mL) which had been prewashed with hydrochloric acid (6 N, 30 mL) 
and then copious amount of water until neutral. The column was desalted with excessive 
water washing (200 mL) and then eluted with hydrochloric acid (0.5 N to 3 N) to give 6 
(2.17 g, quant.) as white solid. 1H NMR (300 MHz, D2O) δ 3.87 (1 H, t, J = 6.6 Hz), 
2.39 (2 H, t, J = 7.2 Hz), 2.02 (3 H, s), 1.81-1.65 (2 H, m), 1.38 (2 H, appar. quintet, 
J=7.5), 1.28-1.12 (4 H, m). 
2.2.2 Construction of plasmids  
A plasmid pAcKRS-pylT-GFP1Amber bearing the genes encoding AcKRS, pylT 
and GFPUV with an amber mutation at position 149 and a His tag at the C-terminus was 
constructed from the pETduet-1 vector (Stratagene Inc.). In this plasmid, AcKRS and 
GFPUV are both under the control of IPTG-inducible T7 promoter and pylT is flanked by 
the lpp promoter and the rrnC terminator (Figure 29).  
2.2.2.1 DNA and protein sequences 
pylT: 
5’-ggaaacctgatcatgtagatcgaatggactctaaatccgttcagccgggttagattcccggggtttccgcca-3’ 
lpp promoter:  
5’-cccatcaaaaaaatattctcaacataaaaaactttgtgtaatacttgtaacgct-3’ 
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Figure 29. Plasmid map for pAcKRS-pylT-GFP1Amber.   
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rrnC terminator:  
5’- atccttagcgaaagctaaggatttttttta-3’ 
AcKRS:  
5’-atgtcagataaaaaaccattagatgttttaatatctgcgaccgggctctggatgtccaggactggcacgctccacaaaatcaa 
gcaccatgaggtctcaagaagtaaaatatacattgaaatggcgtgtggagaccatcttgttgtgaataattccaggagttgtagaa
cagccagagcattcagacatcataagtacagaaaaacctgcaaacgatgtagggtttcgggcgaggatatcaataattttctcac
aagatcaaccgaaagcaaaaacagtgtgaaagttagggtagtttctgctccaaaggtcaaaaaagctatgccgaaatcagtttc
aagggctccgaagcctctggaaaattctgtttctgcaaaggcatcaacgaacacatccagatctgtaccttcgcctgcaaaatca
actccaaattcgtctgttcccgcatcggctcctgctccttcacttacaagaagccagcttgatagggttgaggctctcttaagtcca
gaggataaaatttctctgaatatggcaaagcctttcagggaacttgagcctgaacttgtgacaagaagaaaaaacgattttcagc
ggctctataccaatgatagagaagactacctcggtaaactcgaacgtgatattacgaaatttttcgtagaccggggttttctggag
ataaagtctcctatccttattccggcggaatacgtggagagaatgggtattaataatgatactgaactttcaaaacagatcttccgg
gtggataaaaatctctgcttgaggccaatggttgccccgactattttcaactatgcgcgaaaactcgataggattttaccaggccc
aataaaaattttcgaagtcggaccttgttaccggaaagagtctgacggcaaagagcacctggaagaatttactatggtgaacttct
ttcagatgggttcgggatgtactcgggaaaatcttgaagctctcatcaaagagtttctggactatctggaaatcgacttcgaaatcg
taggagattcctgtatggtctatggggatactcttgatataatgcacggggacctggagctttcttcggcagtcgtcgggccagttt
ctcttgatagagaatggggtattgacaaaccatggataggtgcaggttttggtcttgaacgcttgctcaaggttatgcacggcttta
aaaacattaagagggcatcaaggtccgaatcttactataatgggatttcaaccaatctgtaa-3’ 
GFP1Amber (amber mutation at position 149):  
5’-atgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgt 
cagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatggc
caacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgcca
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tgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaag
gtgatacccttgttaatcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgagtacaact
ataactcacactaggtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaag
atggatccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgt
cgacacaatctgccctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggattaca
catggcatggatgaactctacaaagagctccatcaccatcaccatcactaa-3’ 
AcKRS:  
MSDKKPLDVLISATGLWMSRTGTLHKIKHHEVSRSKIYIEMACGDHLVVNNSRS
CRTARAFRHHKYRKTCKRCRVSGEDINNFLTRSTESKNSVKVRVVSAPKVKKA
MPKSVSRAPKPLENSVSAKASTNTSRSVPSPAKSTPNSSVPASAPAPSLTRSQLDR
VEALLSPEDKISLNMAKPFRELEPELVTRRKNDFQRLYTNDREDYLGKLERDITK
FFVDRGFLEIKSPILIPAEYVERMGINNDTELSKQIFRVDKNLCLRPMVAPTIFNY
ARKLDRILPGPIKIFEVGPCYRKESDGKEHLEEFTMVNFFQMGSGCTRENLEALI
KEFLDYLEIDFEIVGDSCMVYGDTLDIMHGDLELSSAVVGPVSLDREWGIDKPW
IGAGFGLERLLKVMHGFKNIKRASRSESYYNGISTNL 
GFP1Amber: 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLP
VPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHK*VYITADKQKNGI
KANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKR
DHMVLLEFVTAAGITHGMDELYKELHHHHHH 
  
 48 
2.2.2.2 Construction of pBK-AcKRS-pylT 
MbPylRS was amplified from M. barberi genomic DNA purchased from ATCC 
by polymerase chain reaction (PCR) using two primers, 5’-
GAGGAATCCCATATGGATAAAAAACCATTAG-3’ and 5’-
CGTTTGAAACTGCAGTTACAGATTGGTTG-3’. AcKRS (L266V, L270I, Y271F, 
L274A, C313F and D76G)100 was subsequently synthesized by overlap extension PCR 
using MbPylRS as the template and eight oligodeoxynucleotide primers (5’-
GAGGAATCCCATATGGATAAAAAACCATTAG-3’, 5’-
AAATTATTGATATCCTCGCCCGAAACCCTACATCGTTTGC-3’, 5’-
GATGTAGGGTTTCGGGCGAGGATATCAATAATTTTC-3’, 5’-
GTTGAAAATAGTCGGGGCAACCATTGGCCTCAAGCAG-3’, 5’-
GCCCCGACTATTTTCAACTATGCGCGAAAACTCGATAGG-3’, 5’-
CCGAACCCATCTGAAAGAAGTTCACCATAG-3’, 5’-
CTATGGTGAACTTCTTTCAGATGGGTTCGG-3’, and 5’-
CGTTTGAAACTGCAGTTACAGATTGGTTG-3’). Two restriction sites Nde1 at 5’ 
head and Pst1 at 3’ tail were designed into the synthesized AcKRS, which was 
subsequently digested by NdeI and PstI restriction enzymes and cloned into the same 
two sites in a pBK plasmid76 to afford pBK-AcKRS. In pBK-AcKRS, AcKRS is under 
the control of a constitutive glnS promoter. The gene of pylT flanked by the lpp 
promoter at 5’ end and the rrnC terminator at 3’ end was constructed by using overlap 
extension PCR of six oligodeoxynucleotides (5’-
CCCGGGATCCCCCATCAAAAAAATATTCTCAACAT-3’, 5’-
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TTACAAGTATTACACAAAGTTTTTTATGTTGAGAATATTTTTTTG-3’, 5’-
ACTTTGTGTAATACTTGTAACGCTGAATCCGGAAACCTGATCATGTAGAT-3’, 
5’-CTAACCCGGCTGAACGGATTTAGAGTCCATTCGATCTACATGATCAGGT 
TT-3’, 5’-TCAGCCGGGTTAGATTCCCGGGGTTTCCGCCACTGCCCATCCTTAG 
CGAA-3’, and 5’-GAACCCAGATCTTAAAAAAAATCCTTAGCTTTCGCTAAGGA 
TG-3’). Two restriction sites, BamH1 at 5’ end and Bgl11 at 3’ end, were introduced in 
the synthesized DNA, which was subsequently digested by these two enzymes and 
cloned into the BamHI site in pBK-AcKRS to afford pBK-AcKRS-pylT.  
2.2.2.3 Construction of pAcKRS-pylT-GFP1Amber  
Plasmid pAcKRS-pylT-GFP1Amber encodes the AcKRS/pylT pair and 
GFP1Amber with one amber mutation at position 149. Both of AcKRS and GFP1Amber 
were under the control of the T7 promoter. AcKRS was amplified from pBK-AcKRS-
pylT by two oligodeoxynucleotides (5’- 
GATATAACATGTCAGATAAAAAACCATTAGATG-3’, and 5’-
GTCGACCTGCAGTTACAGATTGGTTGAAATCCC-3’). The amplified DNA was 
digested by Pci1 end and Pst1 restriction enzymes and cloned into Nco1 and Pst1 sites 
of the vector of pETduet-1, which was purchased from Stratagene Inc. to afford 
pAcKRS. GFP1Amber was amplified from pleiG-N14989 (a gift from Dr. Peter G. 
Schultz) by two oligodeoxynucleotides (5’-
GAAGGAGATATACATATGAGTAAAGGAGAAG-3’, and 5’-
GACTCGAGGGTACCTTAGTGATGGTGATGGTGATG-3’), digested by NdeI and 
KpnI, and then cloned into NdeI and KpnI restriction sites of pAcKRS to afford 
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pAcKRS-GFP1Amber. The pylT gene with the lpp promoter and the rrnC terminator 
was amplified from pBK-AcKRS-pylT by two oligodeoxynucleotides (5’-
GCTAGATCTGGAAACCTGATGTAGATC-3’, and 5’-
GATACTAGTTGGCGGAAACCCCGGG-3’), digested by SphI, and then cloned into 
the SphI site of pAcKRS-GFP1Amber to afford pAcKRS-pylT-GFP1Amber.  
2.2.3 Protein expression procedure 
To express GFPUV, E. coli Bl21 cells were transformed with pAcKRS-pylT-
GFP1Amber grown in LB medium that contained 100 µg/mL ampicillin and 25 µg/mL 
kanomycin and induced with the addition of 500 µM IPTG when OD600 was 0.6. After 
induction, 2 mM KetoK was subsequently added. Cells were then let grown overnight or 
10 h at 37 degree. Cells were harvested by centrifugation (4500 r.p.m., 20 min, 4 degree) 
and resuspended in 20 mL of lysis buffer (50 mM HEPES, 500 mM NaCl, 10 mM DTT, 
10% glycerol, 0.1% Triton X-100, 5 mM imidazole, and 1 µg/mL lysozyme (pH 7.4)). 
The resuspended cells were sonicated and the lysate was clarified by centrifugation 
(10200 r.p.m., 60 min, 4 degree). The supernatant was decanted and loaded to Ni-NTA 
superspeed agarose (Qiagen Inc.) column on FPLC. The column was washed by 5 × bed 
volume of buffer A that contained 50 mM HEPES, 300 mM NaCl, 5 mM imidazole (pH 
7.5) and then eluted by running a gradient that changed from buffer A to buffer B in 10 × 
bed volume. Buffer B contained 50 mM HEPES, 300 mM NaCl, 250 mM imidazole (pH 
7.5). Proteins were concentrated by Amicon (Millipore, NMWL10 KDa) and analyzed 
by 12% SDS-PAGE (Figure 30). 
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Figure 30. SDS-PAGE analysis of expression of GFPUV with amber mutation. 
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2.2.4 Protein Characterization 
An Agilent (Santa Clara, CA) 1200 capillary HPLC system was interfaced to an 
API QSTAR Pulsar Hybrid QTOF mass spectrometer (Applied Biosystems/MDS Sciex, 
Framingham, MA) equipped with an electrospray ionization (ESI) source. Liquid 
chromatography (LC) separation was achieved using a Phenomenex Jupiter C4 
microbore column (150 × 0.50 mm, 300 Å) (Torrance, CA) at flow rate of 10 µL/min. 
The proteins were eluted using a gradient of (A) 0.1% formic acid versus (B) 0.1% 
formic acid in acetonitrile. The gradient timetable for B was as follows: starting at 2% 
for 5 min, 2-30% in 3 min, 30-60% in 44 min, 60-95% in 8 min, followed by holding the 
gradient at 95% for 5 min, for a total run time of 65 min. The MS data were acquired in 
positive ion mode (500-1800 Da) using spray voltage of +4900 V. BioAnalyst software 
(Applied Biosystems) was used for spectral deconvolution. A mass range of m/z 500-
1800 was used for deconvolution and the output range was 10000-50000 Da using a step 
mass of 0.1 Da and a S/N threshold of 20. 
GFPUV was dissolved in 25 mM of ammonia bicarbonate and denatured at 90 
degree for 15 min. A prepared trypsin solution in 0.01% TFA (pH 3) was added to the 
denatured protein solution (w/w=1:50) and incubated at 37 degree overnight.  
Peptides resulting from tryptic digests were mixed (1:1 v/v) with the matrix (5 
mg/mL α-cyano-4-hydroxycinnamic acid, 50% (v/v) acetonitrile, 10 mM ammonium 
dihydrogen phosphate, and 1% trifluoroacetic acid) and 1 µL of the resulting mixture 
was spotted onto a stainless steel target plate.  Mass spectra and tandem MS spectra were 
collected using an Applied Biosystems 4800 Tof/Tof (Framingham, MA). Collision 
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induced dissociation tandem MS spectra were acquired using air at the medium pressure 
setting and at 2 kV of collision energy.  Tandem MS data was manually interpreted 
using the Data Explorer™ software package (Applied Biosystems, Framingham, MA). 
The transformation of pAcKRS-pylT-GFP1Abmer into BL21 cells and 
subsequent growth in LB medium supplemented with 2 mM KetoK and 500 µM IPTG 
afforded full-length GFPUV incorporated with KetoK (GFP-KetoK) with a yield of 0.5 
mg/L, which was comparable to the expression yield of full-length GFPUV incorporated 
with AcK (GFP-AcK) (0.8 mg/L) when the supplemented amino acid was changed to 5 
mM AcK. The deconvoluted electrospray ionization mass spectrometry (ESI-MS) 
spectrum of GFP-KetoK revealed two intense peaks corresponding to the full-length 
GFP-KetoK with and without N-terminal methionine, respectively (detected: 27,898.9 
Da, 27,767.8 Da; calculated: 27,896 Da, 27,765 Da) (Figure 31A). The site-specific 
incorporation of KetoK at position 149 was further validated by the tandem mass 
spectral analysis of the tryptic KetoK containing fragment of 
LEYNYNSHK*VYITADK (K* denotes KetoK). The K*-containing ions (y8 to y12 and 
b9 to b15) all had the expected mass (Figure 31B). 
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Figure 31. Mass spectra. (A) ESI-MS spectrum of GFP-KetoK, and (B) tandem MS 
spectrum of LEYNYNSHK*VYITADK. 
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2.2.5 Protein labeling 
2.2.5.1 Protein labeled with a fluorescent dye 
To test the efficiency of using the genetically incorporated KetoK to specifically 
label proteins with fluorescent dyes under a mild condition, the purified GFP-KetoK and 
GFP-AcK were both reacted with 1 equiv. Texas Red hydrazide in PBS buffer at 37 
degree, pH 6.3 overnight and then analyzed on a SDS-PAGE gel. The gel was visualized 
by silver staining and fluorescent imaging (Figure 32). Whereas both GFP-KetoK and 
GFP-AcK showed a strong protein band after silver staining, only labeled GFP-KetoK 
had an intense fluorescent band. This indicates that labeling only occurred on GFP-
KetoK and the reaction between the keto group and a hydrazide is specific.  
 
 
 
 
Figure 32. (A) Silver staining. (B) Fluorescent imaging of GFP-KetoK and GFP-AcK 
after their reaction with Texas Red hydrazine dye. 
27000 27400 27800 28200 28600 29000
Mass (Da)
0
20
40
60
80
100
%
 R
el
at
iv
e 
In
te
ns
ity
28213.6028081.00
N
H
NHO H
HN
H S
O H
N
O
O
NH2
A
B
C
D
 56 
2.2.5.2 Protein labeled with biotin derivative 
To further characterize the labeling efficiency, the purified GFP-KetoK was 
reacted with 5 equiv. of biotin alkoxyamine in PBS buffer at 37 degree, pH 6.3 overnight 
and the modified protein was analyzed by ESI-MS (Figure 33B). Two intense peaks 
(28,213.6 Da, 28,081.0 Da) were shown in the deconvoluted ESI-MS spectrum and they 
matched the biotin labeled full-length GFP-KetoK with and without N-terminal 
methionine (calculated mass: 28,209 Da, 28,078 Da), respectively. Given the fact that no 
original full-length GFP-KetoK was detected, the labeling reaction was highly efficient. 
As a control, the same labeling reaction was carried out on wild type GFPUV. The 
deconvoluted ESI-MS spectra of wild type GFPUV before and after the labeling reaction 
showed no difference (Figure 34), demonstrating the reaction specificity between 
KetoK and alkoxyamine probes.  
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Figure 33. (A) Structure of biotin alkoxyamine. (B) ESI-MS spectrum of GFP-KetoK 
after its reaction with biotin alkoxyamine. 
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Figure 34.  ESI-TOF-MS spectra of Wild type GFPUV. Before (A) and after (B) labeling 
reaction with biotin hydroxylamine. No reaction was detected by MS analysis. 
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2.3  Summary 
In summary, we have achieved the genetic incorporation of KetoK into proteins in 
E. coli and applied it to label proteins with different probes. The labeling features high 
specificity and high efficiency under a mild reaction condition. One potential application 
of our method is to site-specifically introduce various biochemical and biophysical 
probes into proteins, including biotin tag, fluorescent labels, NMR probes, EPR probes, 
etc. Moreover, KetoK is an unhydrolysable analogue of AcK that represents one of the 
most important posttranslationally modified amino acids in eukaryotic cells. Since 
protein acetylation is a reversible process catalyzed by enzymes like histone 
acetyltransferases and histone deacetyltransferases, direct incorporation of KetoK into 
proteins in vivo at sites with naturally occurring lysine acetylation will permanently 
install an AcK mimic and may provide an efficient way to decipher the regulation roles 
of acetylation in histones, p53 and other transcription regulatory proteins. 
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3. GENETIC INCORPORATION OF MULTIPLE NAAs INTO  
ONE PROTEIN IN ESCHERICHIA COLI* 
 
3.1 Introduction 
With few exceptions, the genetic codes of all known organisms specify the same 
20 canonical amino acid building blocks.102 However, it is clear that many proteins 
require additional chemical groups beyond what the 20 building blocks can provide to 
carry out their native functions.34 Many of these groups are installed into proteins 
through covalent posttranslational modifications, such as acetylation, methylation, 
phosphorylation, sulfation, etc. These modifications, to a great extent, expand the amino 
acid inventory of proteins by assimilating NAAs and grant proteins expanded 
opportunities for catalysis, mediating signal transduction, integration of information at 
many metabolic intersections, and alteration of cellular locations. The diversity of these 
covalent modifications greatly exceeds the number of proteins predicted by DNA coding 
capacities, leading to proteomes in higher organisms 2-3 orders of magnitude more 
complex than the encoding genomes and therefore adding a great complexity to the 
functional investigation of a lot of proteins.34  
A major challenge in studying posttranslationally modified proteins is that they 
exist typically as a mixture of different forms, making it difficult to purify uniquely  
 
*Reprinted with permission from “A Convenient Method for Genetic Incorporation of 
Multiple Noncanonical Amino Acids into One Protein in Escherichia Coli” by Huang, 
Y., Russell, W. K., Wan, W., Pai, P. J., Russell, D. H., Liu, W., 2010. Mol. Biosyst., 6, 
683-686, Copyright [2010] by Royal Society of Chemistry. 
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modified forms from their natural sources. For this reason, a variety of approaches have 
been developed to synthesize proteins with defined posttranslational modifications that 
can be easily isolated. One of these approaches uses the nucleophilicity of cysteine to 
install N-ε-methylated lysine analogs into proteins. Native chemical ligation and its 
extension, expression protein ligation, have also been used to install NAAs into 
proteins.74 These two approaches provide great opportunities to study functional roles of 
posttranslational modifications. However, they both are in vitro semisynthetic 
techniques. In addition, NAAs installed by cysteine replacement are not exactly the same 
as what exist in nature; incorporating NAAs into internal sites of proteins using native 
chemical ligation is also problematic. An alternative NAA installation approach that can 
be carried out in vivo is the genetic incorporation of NAAs directly into proteins during 
translation in live cells. This approach relies on the read-through of an in-frame amber 
(UAG) stop codon in mRNA by an amber suppressor tRNA specifically acylated with a 
NAA by an evolved aaRSs.103 One essential advantage of this approach is that a NAA 
can be installed at any site of a protein regardless of the protein size. Using this 
approach, two NAAs, O-sulfo-L-tyrosine and AcK which occur naturally in 
posttranslationally modified proteins have been incorporated into proteins in E. coli.100, 
104 Although the genetic NAA incorporation approach has opened a new avenue for 
functional studies of posttranslationally modified proteins both in vitro and in vivo, it has 
its intrinsic limitation. The method relies on the suppression of an amber stop codon and 
has to compete with the release factor-1 (RF1)-mediated translation termination which 
terminates protein translation at the amber codon (Figure 35).105 In general, the 
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suppression efficiency for a single amber codon is limited to 10-20%.106 As the number 
of amber codons in a gene increases, the expression yield of the full-length protein 
decreases multiplicatively. This creates a huge difficulty in the expression of proteins  
 
 
 
 
Figure 35. Scheme for RF-1 termination. 
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with multiple posttranslational modifications, which are abundant in nature. For 
example, seven acetylation sites have been discovered in histone 3.107 
Different acetylation patterns at these sites regulate cellular processes ranging 
from transcription activation to DNA repair. A modified genetic NAA incorporation 
approach that allows synthesis of proteins with multiple modifications is critical for their 
functional investigation and is in dire need. Chin et al. recently developed an elegant 
system that used an evolved orthogonal ribosome (ribo-X) to achieve the incorporation 
of two NAAs into one protein.106 As demonstrated here, we have developed a simpler 
method for the incorporation of multiple NAAs into one protein in E. coli simply by 
overexpressing the C-terminal domain of the large ribosomal subunit protein L11 and 
applied it to synthesize green fluorescent protein (GFPUV) with three AcKs.  
The underlying reason of a low NAA incorporation efficiency is due to RF-1 
mediated release of premature peptide from ribosome at a designated amber codon. A 
decrease in the RF1-mediated translation termination rate will certainly enhance the 
amber suppression efficiency and make it possible to incorporate multiple NAAs into 
one protein. To achieve this goal, we decided to modify the large ribosomal subunit 
protein L11 in E. coli. L11 is a highly conserved small ribosomal protein that associates 
23S rRNA and contains two domains, N- and C-terminal domains linked together by a 
small peptide hinge (Figure 36).108 It has been suggested from biochemical studies that 
L11 plays an important role in the RF1-mediated peptide release.109, 110 Knockout of the 
N-terminal domain of L11 (L11N) from E. coli led to a slightly slower cell growth but 
with a much higher amber suppression rate. However, E. coli lacking the entire L11   
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Figure 36. Crystal structure of the L11-RNA complex. PBD: 1MMS. 
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protein was thermosensitive and showed a drastically decreased cell growth rate.109 
These indicate that the C-terminal domain of L11 (L11C) alone efficiently binds 23S 
rRNA and the resulted ribosome maintains almost regular protein translation efficiency 
but with a high amber suppression rate. The in vitro analysis also proved 4-6 folds 
reduction in the RF1-mediated termination efficiency when ribosome did not contain 
L11N.110 Based on these observations, we hypothesized that overexpression of L11C 
inside E. coli should efficiently replace L11 in ribosome, consequently decrease the 
RF1-meidated translation termination at amber codon, and increase amber suppression 
efficiency. This enhanced amber suppression level may allow the incorporation of 
multiple NAAs into one protein (Figure 37).   
We chose to demonstrate our hypothesis by the incorporation of multiple AcKs 
into one protein in E. coli. Mutant AcKRSs that are specific for AcK have been evolved 
from Methanosarcina barkeri PylRS. Together with M. barkeri pylT, the cognate amber 
suppressor tRNA of PylRS, these mutant variants have been used to incorporate AcK 
into proteins in E. coli.100 
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Figure 37. Scheme for incorporation of multiple NAAs into one protein. 
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3.2 Experiments and results 
3.2.1   Construction of plasmids 
I chose to demonstrate our hypothesis by the incorporation of multiple AcKs into 
one protein in E. coli. Thus, pAcKRS-pylT-GFP1Amber was used. The gene for 
overexpression L11C had been cloned into pET30a to generate pET-L11C. One and two 
additional amber codons had been introduced into pAcKRS plasmid separately to afford 
pAcKRS-pylT-GFP2Amber and pAcKRS-pylT-GFP3Amber. These three pAcKRS 
plasmids together with pET-L11C had been used to express GFPUV with one and two 
and three UAAs (Figure 38). 
The construction of pAcKRS-pylT-GFP1Amber, pET-L11C, pAcKRS-pylT-
GFP2Amber, and pAcKRS-pylT-GFP3Amber all followed standard cloning and 
QuikChange site-directed mutagenesis procedures using Platinum Pfx (Invitrogen) and 
PfuTurbo (Stratagene) DNA polymerases. All the plasmid structures have been 
confirmed by sequencing. All oligonucleotide primers were purchased from Integrated 
DNA Technologies, Inc. 
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Figure 38. Plasmid maps.  
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3.2.1.1 DNA and protein sequences 
GFP2Amber:  
5’-atgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctg 
tcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatgg
ccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgcc
atgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaa
ggtgatacccttgttaatcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgagtacaac
tataactcacactaggtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaa
gatggatccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacct
gtcgacatagtctgccctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggatta
cacatggcatggatgaactctacaaagagctccatcaccatcaccatcactaa-3’ 
GFP3Amber:  
5’-atgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctg 
tcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatgg
ccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgcc
atgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaa
ggtgatacccttgttaatcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgagtacaac
tataactcacactaggtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaa
gatggatccgttcaactagcagaccattatcaatagaatactccaattggcgatggccctgtccttttaccagacaaccattacctg
tcgacatagtctgccctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggattaca
catggcatggatgaactctacaaagagctccatcaccatcaccatcactaa-3’  
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GFP2Amber':  
5’-atggcatagagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaa 
ttttctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttc
catggccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaaga
gtgccatgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagt
ttgaaggtgatacccttgttaatcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgagt
acaactataactcacactaggtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaaca
ttgaagatggatccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccatt
acctgtcgacatagtctgccctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctggg
attacacatggcatggatgaactctacaaagagctccatcaccatcaccatcactaa-3’ 
L11C:  
5’-atgaccaagaccccgccggcagcagttctgctgaaaaaagcggctggtatcaagtctggttccggtaagccgaacaaag 
acaaagtgggtaaaatttcccgcgctcagctgcaggaaatcgcgcagaccaaagctgccgacatgactggtgccgacattga
agcgatgactcgctccatcgaaggtactgcacgttccatgggcctggtagtggaggactaa-3’ 
GFP2Amber: 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLP
VPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHK*VYITADKQKNGI
KANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTK*SALSKDPNEK
RDHMVLLEFVTAAGITHGMDELYKELHHHHHH 
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GFP3Amber: 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLP
VPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHK*VYITADKQKNGI
KANFKIRHNIEDGSVQLADHYQK*NTPIGDGPVLLPDNHYLSTK*SALSKDPNEK
RDHMVLLEFVTAAGITHGMDELYKELHHHHHH 
GFP2Amber':  
MAK*SKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTG
KLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG
NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHK*VYITADKQ
KNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDP
NEKRDHMVLLEFVTAAGITHGMDELYKELHHHHHH 
L11C:  
MTKTPPAAVLLKKAAGIKSGSGKPNKDKVGKISRAQLQEIAQTKAADMTGADI
EAMTRSIEGTARSMGLVVED 
3.2.1.2 Construction of pAcKRS-pylT-GFP2Amber 
Plasmid pAcKRS-pylT-GFP2Amber was derived from pAcKRS-pylT-
GFP1Amber with an addition amber mutation at position 204. The mutagenesis was 
carried out by the standard QuikChange site-directed mutagenesis procedure using 
PfuTurbo DNA polymerase and two oligonucleotides, 5’-
CTTTCGAAAGGGCAGACTATGTCGACAGGTAATG-3’ and 5’-
CATTACCTGTCGACATAGTCTGCCCTTTCGAAAG-3’. 
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3.2.1.3 Construction of pAcKRS-pylT-GFP3Amber 
Plasmid pAcKRS-pylT-GFP3Amber was derived from pAcKRS-pylT-
GFP2Amber with an additional amber mutation at position 184. The mutagenesis was 
carried out by the standard QuikChange site-directed mutagenesis procedure using 
PfuTurbo DNA polymerase and two oligonucleotides, 5’-
ATCGCCAATTGGAGTATTCTATTGATAATGGTCTGC-3’ and 5’-
GCAGACCATTATCAATAGAATACTCCAATTGGCGAT-3’. 
3.2.1.4 Construction of pAcKRS-pylT-GFP2Amber' 
Plasmid pAcKRS-pylT-GFP2Amber’ was derived from pAcKRS-pylT-
GFP1Amber with an addition amber mutation at position 2. The mutagenesis was carried 
out by the standard QuikChange site-directed mutagenesis procedure using PfuTurbo 
DNA polymerase and two oligonucleotides, 5’-
GATATACATATGGCATAGAGTAAAGGAGAAGAA-3’ and 5’-
CATTACCTGTCGACATAGTCTGCCCTTTCGAAAG-3’. 
3.2.1.5 Construction of pET-L11C 
Plasmid pET-L11C contains the gene of L11C whose transcription is under the 
control of T7 promoter. L11C gene was amplified from the genomic DNA of E. coli by 
standard PCR using two primers, 5’-
GGAGATATACATATGACCAAGACCCCGCCGGCA-3’ and 5’-
GTCGTCGGTACCTTAGTCCTCCACTACCAG-3’. The amplified DNA was digested 
by NdeI and KpnI restriction enzymes and cloned into NdeI and KpnI sites in pET30a 
(Stratagene Inc.) to afford pET-L11C. 
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3.2.2 Protein expression procedure 
To express different kinds of GFPUV variants, E. coli Bl21 cells was transformed 
with pAcKRS-pylT-GFP1Amber, pAcKRS-pylT-GFP2Amber, or pAcKRS-pylT-
GFP3Amber together with or without pET-L11C. Cells transformed with one plasmid 
were grown in LB media that contained 100 µg/mL ampicillin and induced with the 
addition of 500 µM IPTG when OD600 reached 0.6. 5 mM AcK and 5 mM nicotinamide 
were subsequently added into the media 0.5 h after induction. Nicotinamide was 
inhibitor for the deacetylation of AcK, which was common inside of E. coli. Cells were 
then let grown for 10 h at 37 degree. The protein expression in cells transformed with 
two plasmids followed exactly same procedures except the addition of 25 µg/mL 
kanamycin into the media to force cells to maintain pET30-L11C. The GFPUV 
expression in cells transformed with either one or two plasmids at the absence of AcK 
also followed the same procedures. GFPUV were purified as previous descried. 
3.2.3 The study for L11C to increase the protein expression level for single 
incoproation of NAA 
The plasmid pAcKRS-pylT-GFP1Amber that bear the genes encoding GFPUV 
with an amber mutation at position 149 was used to test our hypothesis. The 
transformation of BL21 cells with this plasmid and subsequent growing cells in LB 
medium supplemented with 5 mM AcK and 500 µM IPTG afforded full-length GFPUV 
incorporated with AcK at position 149 (GFP-AcK) with a yield of ~0.8 mg/L. Trace 
amount of full-length GFPUV was expressed when AcK was absent in LB media (Figure 
39).  
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Figure 39. SDS-PAGE analysis of GFP-AcK expressed in the absence and presence of 
L11C.  
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We then tested whether overexpression of L11C could improve amber 
suppression rate. Transformation of BL21 cells with both pAcKRS-pylT-GFP1Amber 
and pET-L11C and subsequent growth in LB medium with the addition of 5 mM AcK 
and 500 µM IPTG led to GFP-AcK production with a yield of ~3.5 mg/L which was four 
times higher than that from cells transformed only with pAcKRS-pylT-GFP1Amber. The 
electrospray ionization mass spectrometry (ESI-MS) of full-length GFPUV purified from 
cells transformed with two plasmids revealed two intense peaks corresponding to GFP-
AcK with and without the N-terminal methionine, respectively (Table 2 and Figure 40).  
The tandem mass spectrum of the tryptic AcK-containing fragment of 
LEYNYNSHK*VYITADK (K* denotes AcK) validated the incorporation of AcK at 
position 149. The presence of K* containing ions (y8 to y15 and b9 to b15) all had the 
expected mass (Figure 41).  
 
 
 
 
Figure 40. ESI spectrum of GFP-AcK. 
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Figure 41. Tandem MS spectrum of LEYNYNSHK*VYITADK from GFP-AcK. 
Similar spectra were obtained from GFP-2AcK and GFP-3AcK. K* is at position 149. 
 
 
Table 2. GFPUV Expression Yields and MS Characterization 
 
Protein[a] L11C 
coexpression 
Concentration 
(mg/L) 
Calculated Mass 
(Da) 
Actual Mass 
(Da) 
GFP - 56 26645[b] 26646 
GFP-
AcK 
+ 3.5 27766[b] 
27897[c] 
27767 
27898 
- 0.8   
GFP-
2AcK 
+ 0.2 27808[b] 
27939[c] 
27809 
27940 
- N.D.   
GFP-
3AcK 
+ 0.1 27850[b] 
27981[c] 
27850 
27981 
- N.D.   
 
[a] Proteins were expressed in the presence of 5 mM AcK and 500 µM IPTG. [b] 
Molecular mass of full-length protein without N-terminal methionine. [c] Molecular 
mass of full-length protein with N-terminal methionine. 
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            To test whether L11C overexpression improves the basal level of amber 
suppression, the BL21 cells transformed with both pAcKRS-pylT-GFP1Amber and 
pET-L11C were grown in LB medium supplemented only with 500 µM IPTG. In the 
absence of AcK, full-length GFPUV was expressed with a yield of 0.2 mg/L, indicating a 
significant basal amber suppression improvement. Since the evolved AcKRS still 
showed low activity toward natural amino acids in LB medium,100 this basal amber 
suppression improvement may represent the improved ability of AcKRS to incorporate 
natural amino acids into proteins. ESI-MS of the purified full-length GFPUV expressed in 
this condition revealed five peaks (Figure 42), of which one (27766 Da) matched the 
mass of GFP-AcK without N-terminal methionine but the other four (27710 Da, 27725 
Da, 27782 Da, and 27842 Da) were not identified in ESI-MS of GFP-AcK purified from 
the same cells growing in the presence of AcK.  
 
 
 
 
Figure 42. ESI mass spectrum for GFP-AcK misincorporation. 
 78 
These indicate the presence of AcK efficiently inhibits the incorporation of other 
amino acids, assuring the high fidelity of AcK incorporation. These experiments 
demonstrated that the overexpression of L11C indeed enhances amber suppression 
efficiency and maintains high NAA incorporation fidelity as well. 
3.2.4 The study for L11C to increase the protein expression level for multiple 
incoproation of NAAs into one protein 
We first tested the feasibility to use the L11C overexpression to incorporate two 
AcKs into one protein in E. coli. An additional amber mutation was introduced into 
position 204 of the GFPUV gene in pAcKRS-pylT-GFP1Amber to afford pAcKRS-pylT-
GFP2Amber. Together with or without pET-L11C, the modified plasmid was used to 
transform BL21 cells. Subsequent cell growth in LB medium supplemented with 5 mM 
AcK and 500 µM IPTG led to the production of GFPUV incorporated with AcKs at 
positions 149 and 204 (GFP-2AcK) in cells that were transformed with two plasmids 
(Figure 43). The expression yield was ~0.2 mg/L. In contrast, GFP-2AcK was not 
detected in cells that were transformed with only pAcKRS-pylT-GFP2Amber.  
The ESI-MS analysis of the purified GFP-2AcK from cells transformed with two 
plasmids confirmed the expected incorporation (Figure 44).  
The incorporation of AcKs at positions 149 (same as GFP-AcK, not showing) 
and 204 was also independently confirmed by tandem mass spectral analysis of tryptic 
and endoproteinase Asp-N-digested AcK-containing fragments (Figures 45).  
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Figure 43. SDS-PAGE analysis of GFP-2AcK expressed in the absence and presence of 
L11C. 
 
 
 
 
Figure 44. ESI spectrum of GFP-2AcK. 
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Figure 45. Tandem MS spectrum of DNHYLSTK*SALSK from GFP-2AcK. Almost 
identical spectra were obtained from GFP-3AcK. K* is at position 204. 
 
 
 
 
Figure 46. SDS-PAGE analysis of GFP-3AcK expressed in the absence and presence of 
L11C. 
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To test the limit of our strategy, we carried on to incorporate three AcKs into 
GFPUV in E. coli. One more amber mutation was installed at position 184 of the GFPUV 
gene in the plasmid pAcKRS-pylT-GFP2Amber to afford pAcKRS-pylT-GFP3Amber. 
Together with pET-L11C, this plasmid was used to express GFPUV incorporated with 
three AcKs (GFP-3AcK) in E. coli, following the exactly same procedures used in GFP-
2AcK expression. GFP-3AcK was expressed in cells transformed with both pAcKRS-
pylT-GFP3Amber and pET-L11C with a final yield of ~0.1 mg/L. No GFP-3AcK was 
detected in cells transformed only with pAcKRS-pylT-GFP3Amber (Figure 46).  
ESI-MS of purified full-length GFP-3AcK and tandem MS analysis of 
proteolytic AcK-containing peptide fragments confirmed that three AcKs were indeed 
incorporated into positions 149, 184, and 204 (Figure 47 and Figure 48).  
 
 
 
 
Figure 47. ESI spectrum of GFP-3AcK. 
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Figure 48. Tandem MS spectrum of DHYQK*NTPIG from GFP-3AcK. K* is at 
position 184. 
  
 83 
Although the enhancement of amber suppression rate by overexpressing L11C 
allowed the expression of GFP-2AcK and GFP-3AcK in E. coli, the drastic decline of 
the expression level from GFP-AcK to GFP-2AcK was of a big concern. Based on our 
previous experiences, we think this might be due to protein folding difficulty when AcK 
is introduced at position 204 because we frequently observed that the choice of the 
position to introduce a NAA into a protein usually affects the protein expression yield to 
a great extent. To approve the drastic expression level decrease is due to the choice of 
the position, we carried out to express GFPUV incorporated with two AcKs at positions 2 
and 149 (GFP-2AcK'). An additional amber mutation was introduced into position 2 of 
the GFPUV gene in pAcKRS-pylT-GFP1Amber to afford pAcKRS-pylT-GFP2Amber' in 
which an alanine insertion was also introduced into the GFPUV gene between the start 
codon ATG and the amber codon at position 2 to relieve possible difficulty of protein 
translation when ribosome immediately meets a stop codon right after a start codon. 
Together with or without pET-L11C, the modified plasmid was used to transform BL21 
cells. Subsequent cell growth in LB medium supplemented with 5 mM AcK and 500 µM 
IPTG led to the production of GFP-2AcK' with an expression yield of ~1.4 mg/L that is 
seven times higher than the GFP-2AcK expression under the same condition (Figure 49).  
Cells transformed with only pAcKRS-pylT-GFP2Amber' yielded non-detectable 
GFP-2AcK'. This demonstrates that the low protein expression level of GFP-2AcK is a 
consequence of choosing position 204 to introduce the second AcK that may affect 
protein folding. 
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Figure 49. ESI spectrum of GFP-2AcK’. 
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3.2.5 Unpublished results 
To further test the generality of our approach, another protein, dihydrofolate 
reductase (DHFR) was used as an example. DHFR was widely used for demonstration 
due to its high expression yield. The genes codes for DHFR, DHFR1Amber, 
DHFR2Amber replaced the position of GFP in the pAcKRS-pylT-GFP1Amber to 
obtain pAcKRS-pylT-DHFR, pAcKRS-pylT-DHFR1Amber and pAcKRS-pylT-
DHFR2Amber. E. coli Bl21 cells transformed with pAcKRS-pylT-DHFR1Amber, or 
pAcKRS-pylT-DHFR2Amber together with or without pET-L11C were let grow to 
express the desired proteins. 
3.2.5.1 DNA and protein sequences 
DHFR: 
5’-atgatcagtctgattgcggcgttagcggtagatcgcgttatcggcatggaaaacgccatgccgtggaacctgcctgccgat 
ctcgcctggtttaaacgcaacaccttaaataaacccgtgattatgggccgccatacctgggaatcaatcggtcgtccgttgccag
gacgcaaaaatattatcctcagcagtcaaccgggtacggacgatcgcgtaacgtgggtgaagtcggtggatgaagccatcgc
ggcgtgtggtgacgtaccagaaatcatggtgattggcggcggtcgcgtttatgaacagttcttgccaaaagcgcaaaaactgta
tctgacgcatatcgacgcagaagtggaaggcgacacccatttcccggattacgagccggatgactgggaatcggtattcagcg
aattccacgatgctgatgcgcagaactctcacagctattgctttgagattctggagcggcgggagctccatcaccatcaccatca
ctaa-3’ 
DHFR1Amber: 
5’-atgatcagtctgattgcggcgttagcggtagatcgcgttatcggcatggaaaacgccatgccgtggaacctgcctgccgat 
ctctagtggtttaaacgcaacaccttaaataaacccgtgattatgggccgccatacctgggaatcaatcggtcgtccgttgccag
gacgcaaaaatattatcctcagcagtcaaccgggtacggacgatcgcgtaacgtgggtgaagtcggtggatgaagccatcgc
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ggcgtgtggtgacgtaccagaaatcatggtgattggcggcggtcgcgtttatgaacagttcttgccaaaagcgcaaaaactgta
tctgacgcatatcgacgcagaagtggaaggcgacacccatttcccggattacgagccggatgactgggaatcggtattcagcg
aattccacgatgctgatgcgcagaactctcacagctattgctttgagattctggagcggcgggagctccatcaccatcaccatca
ctaa-3’ 
DHFR2Amber: 
5’-atgatcagtctgattgcggcgttagcggtagatcgcgttatcggcatggaaaacgccatgccgtggaacctgcctgccgat 
ctctagtggtttaaacgcaacaccttaaataaacccgtgattatgggccgccatacctgggaatcaatcggtcgtccgttgccag
gacgcaaaaatattatcctcagcagtcaaccgggtacggacgatcgcgtaacgtgggtgaagtcggtggatgaagccatcgc
ggcgtgtggtgacgtaccagaaatcatggtgattggcggcggtcgcgtttatgaacagttcttgccaaaagcgcaaaaactgta
tctgacgcatatcgacgcagaagtggaaggcgacacccatttcccggattacgagccggatgactgggaatcggtattcagcg
aattccacgatgctgatgcgtagaactctcacagctattgctttgagattctggagcggcgggagctccatcaccatcaccatca
ctaa-3’ 
DHFR: 
MISLIAALAVDRVIGMENAMPWNLPADLAWFKRNTLNKPVIMGRHTWESIGRP
LPGRKNIILSSQPGTDDRVTWVKSVDEAIAACGDVPEIMVIGGGRVYEQFLPKA
QKLYLTHIDAEVEGDTHFPDYEPDDWESVFSEFHDADAQNSHSYCFEILERREL
HHHHHH 
DHFR1Amber: 
MISLIAALAVDRVIGMENAMPWNLP*DLAWFKRNTLNKPVIMGRHTWESIGRPL
PGRKNIILSSQPGTDDRVTWVKSVDEAIAACGDVPEIMVIGGGRVYEQFLPKAQ
KLYLTHIDAEVEGDTHFPDYEPDDWESVFSEFHDADAQNSHSYCFEILERRELH
HHHHH 
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DHFR2Amber: 
MISLIAALAVDRVIGMENAMPWNLP*DLAWFKRNTLNKPVIMGRHTWESIGRPL
PGRKNIILSSQPGTDDRVTWVKSVDEAIAACGDVPEIMVIGGGRVYEQFLPKAQ
KLYLTHIDAEVEGDTHFPDYEPDDWESVFSEFHDADA*NSHSYCFEILERRELHH
HHHH 
3.2.5.2 Construction of pAcKRS-pylT-DHFR 
Plasmid pAcKRS-pylT-DHFR was derived from pAcKRS-pylT-GFP1Amber 
with the replacement of GFP1Amber with DHFR. DHFR was amplified from E. coli 
Top10 by two oligodeoxynucleotides, (5’- 
GAGATATACATATGATCAGTCTGATTGCGGCG-3’, and 5’-
GTGATGGAGCTCCCGCCGCTCCAGAATCTC-3’), digested by NdeI and SacI, and 
then cloned into NdeI and SacI restriction sites of pAcKRS-pylT-GFP1Amber to afford 
pAcKRS-pylT-DHFR. 
3.2.5.3 Construction of pAcKRS-pylT-DHFR1Amber 
Plasmid pAcKRS-pylT-DHFR1amber was derived from pAcKRS-pylT-DHFR 
with an additional amber mutation at position 26. The mutagenesis was carried out by 
the standard QuikChange site-directed mutagenesis procedure using PfuTurbo DNA 
polymerase and two oligonucleotides, 5’-
CTGCCTGCCGATCTCTAGTGGTTTAAACGCAAC-3’, and 5’-
GTTGCGTTTAAACCACTAGAGATCGGCAGGCAG-3’. 
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3.2.5.4 Construction of pAcKRS-pylT-DHFR2Amber 
Plasmid pAcKRS-pylT-DHFR2amber was derived from pAcKRS-pylT-
DHFR1Amber with an additional amber mutation at position 146. The mutagenesis was 
carried out by the standard QuikChange site-directed mutagenesis procedure using 
PfuTurbo DNA polymerase and two oligonucleotides, 5’-
CACGATGCTGATGCGTAGAACTCTCACAGCTAT-3’ and 5’-
ATAGCTGTGAGAGTTCTACGCATCAGCATCGTG-3’.  
3.2.5.5 DHFR mutants expression and characterization 
The expression and purification of wtDHFR, DHFR-AcK, and DHFR-2AcK 
were followed the methods described above. DHFR-AcK and DHFR-2AcK were 
expressed in the absence or presence of L11C. In the presence of L11C, both DHFR-
2AcK and DHFR-2AcK was obtained. As expected, in the absence of L11C, smaller 
amount of DHFR-AcK was expressed, and no detectable amount of DHFR-2AcK was 
expressed (Figure 50).  
The electrospray ionization mass spectrometry (ESI-MS) of full-length DHFR, 
DFHR1Amber, and DHFR2Amber purified from cells transformed with two plasmids 
confirmed the desired incorporation (Figure 51).  
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Figure 50. SDS-PAGE analysis of DHFR mutants expression. WtDHFR was loaded 1/5 
of amount of other proteins. No DHFR-2AcK was expressed in the absence of L11C.  
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Figure 51. ESI spectra for DHFR, DHFR-AcK, and DHFR-2AcK. 
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3.3 Summary 
In summary, we have devised a convenient approach for genetic incorporation of 
multiple NAAs into one protein in E. coli and used it successfully to incorporate three 
AcKs into GFPUV. To our knowledge, this is the first report that demonstrated the 
synthesis of a protein with three acetylations in E. coli. Given the fact that lysine 
acetylation represents one of the most important posttranslational modifications that is 
crucial in modulating chromatin-based transcriptional control and shaping inheritable 
epigenetic programs, this reported method will find broad applications in deciphering the 
regulatory roles of acetylations in histones, p53 and other transcription regulatory 
proteins.111, 112 Besides the incorporation of multiple AcKs into a protein, the developed 
method can be virtually used to incorporate multiple copies of any genetic encoded NAA 
into single proteins. The amber suppression improvement achieved by the reported 
approach can also be directly used to increase expression yield of NAA-incorporated 
proteins in E. coli in general. Since the genetic NAA incorporation has been applied for 
constructing therapeutic proteins, the application of this approach in therapeutic protein 
production is also anticipated.113 Another potential application of the reported approach 
is to use it to achieve the incorporation of two distinct NAAs. We are currently pursuing 
encoding two distinct NAAs in one protein by amber and ochre (UAA) codons, 
respectively. Since the translation termination at the ochre codon is also partly mediated 
by RF1, the overexpression of L11C should enhance both amber and ochre suppression 
rates and allow the expression of proteins incorporated with two distinct NAAs with 
reasonable yields. Moreover, our method and the ribo-X system developed by Chin et al. 
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are independent.106 The integration of two methods could further enhance the amber 
suppression rate and may allow the use of amber codon as a regular sense codon. 
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4. A FACILE SYSTEM FOR GENETIC INCORPORATION OF TWO 
DIFFERENT NONCANONICAL AMINO ACIDS INTO 
ONE PROTEIN IN ESCHERICHIA COLI＊ 
 
4.1 Introduction 
Since the first report in 1998,76 genetic incorporation of NAAs into proteins at 
amber UAG codons in living cells using orthogonal aaRS-amber suppressor tRNA 
(tRNACUA) pairs has flourished.114 Evolved MjTyrRS-  pairs together with the 
naturally occurring wild-type or evolved PylRS- pylT pairs have enabled the 
incorporation of more than 70 NAAs into proteins in E. coli.87, 100, 103, 115-119 Although the 
incorporation of these NAAs equipped with unique chemical properties and reactivities 
into proteins has dramatically increased our ability to manipulate protein structure and 
function, there still exists one major limitation for the technique. Namely, the technique 
in general only allows the incorporation of a single NAA into a single protein because 
the amber codon is the only one available for the incorporation of NAAs and the 
nonsense suppression rate in living cells is low. We have previously demonstrated the 
incorporation of up to three AcKs at amber mutation sites of GFPUV in E. coli under an 
enhanced amber suppression condition.120  
 
*Repreinted with permission from “A Facile System for Genetic Incorporation of Two 
Different Noncanonical Amino Acids into One Protein in Escherichia Coli” by Wan, W.， 
Huang, Y., Wang, Z., Russell, W. K., Pai, P. J., Russell, D. H., Liu, W. R., 2010. Angew. 
Chem. Int. Ed. Engl., 49, 3211-3214, Copyright [2010] WILEY-VCH Verlag GmbH & 
Co. KGaA, Weinheim. 
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The crystal structure of the PylRS-pylT complex revealed no direct interaction 
between PylRS and the anticodon region of pylT.64 We suspected that mutation of the 
anticodon of pylT might not affect its interaction with PylRS and the mutated PylRS-
pylT pair could be used to suppress a blank codon such as opal UGA codon, ochre UAA 
codon or even a four-base codon UAGA (Figure 52). Therefore, I aimed to utilize one 
additional blank codon suppressed by PylRS mutants to couple with amber codon 
suppressed by MjTyrRS mutants to facilitate the incorporation of two different NAAs 
into one protein. Herein, we show that the PylRS-pylT pair can be mutated to suppress 
the ochre UAA codon and the mutated pair can be coupled with an evolved MjTyrRS-
 pair to efficiently incorporate two different NAAs at two defined sites of a 
single protein in E. coli by both amber and ochre suppressions.  
 
 
 
 
Figure 52. PylT structure and anticodon design.	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4.2 Experiments and results 
4.2.1    Synthesis of 2, 3, and 6  
4.2.1.1 Synthetic schemes 
Compounds 2 and 3 were synthesized in a divergent route (Scheme 2). 
Compound 6 was synthesized in one step following the literature protocol for similar 
compounds (Scheme 3).121 
 
 
Scheme 2. Synthetic Route of 2 and 3	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Scheme 3. Synthetic Route of 6 
 
 
 
 
4.2.1.2 Boc-Lys(Z)-OMe (8)122 
To a suspension of Boc-Lys(Z)-OH (7, 40.3 g, 0.106 mol) and potassium 
carbonate (27.6 g, 0.200 mol) in DMF (200 mL) was added iodomethane (9.90 mL, 
0.159 mol), and the mixture was stirred at room temperature for 30 h. The mixture was 
filtered, and the filter cake was washed with ethyl acetate (50 mL), dissolved in water 
(100 mL), and extracted with ethyl acetate (100 mL × 2). All the ethyl acetate solutions 
were combined with the filtrate, and the solution was evaporated under vacuum until 
most of the DMF has been removed. The residue was redissolved in ether (250 mL), 
washed with water (100 mL) and brine (50 mL), dried (Na2SO4), and evaporated to 
afford 8 (41.8 g, quant.) as yellow oil. The material was pure enough for the next-step 
reaction without further treatment. 
A fraction of pure 8 was obtained by flash chromatography (EtOAc/hexanes, 1:5) 
for characterization: Rf = 0.35 (EtOAc/hexanes, 1:2); [α]D22 +6.1(c 2.90, CHCl3) [α]D20 
+7.8 (c 3.93, CHCl3)); 1H NMR (CDCl3, 500 MHz) δ 7.36-7.35 (m, 4 H), 7.33-7.30 (m, 
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1 H), 5.12 (d, 1 H, J = 8.5 Hz), 5.09 (s, 2 H), 4.89 (bs, 1 H), 4.30-4.26 (m, 1 H), 3.73 (s, 
3 H), 3.19 (dt, 2 H, J = 6.7, 6.7 Hz), 1.80-1.77 (m, 1 H), 1.68-1.60 (m, 1 H), 1.55-1.49 
(m, 2 H), 1.43 (s, 9 H), 1.39-1.33 (m, 2 H); 13C NMR (CDCl3, 125 MHz) δ 173.5, 156.6, 
155.6, 136.7, 128.7, 128.32, 128.27, 80.1, 66.8, 53.3, 52.5, 40.8, 32.5, 29.5, 28.5, 22.5.   
In order to check the optical purity of 8, a small amount of racemic 8 was 
obtained in the same way starting from racemic 7. The racemic sample was dissolved in 
isopropanol (10 mg/mL), filtered over 0.2 µm PTFE membrane filter (VWR), and 
injected (4 µL) onto the Shimadzu LC system equipped with a Chiralpak IB column. 
The sample was isocratically eluted with 10% isopropanol in hexanes and the peaks 
were monitored at 210 nm. The (S)-enantiomer was eluted at 12.72 min and the (R)-
enantiomer was eluted at 11.59 min. A sample of 8 (10 mg/mL, 2 µL) was subsequently 
analyzed under the same conditions, and its e.e. was determined to be 100%.  
4.2.1.3 N-α-Boc-N-ε-propargyloxycarbonyl-L-lysine methyl ester (9) 
A solution of 8 (3.61 g, 9.15 mmol) in methanol (100 mL) was hydrogenated 
under a H2 balloon in the presence of palladium on alumina (10 wt.% Pd, 0.61 g, 0.57 
mmol) at room temperature for 4 h, and TLC analysis showed a complete conversion. 
The mixture was then filtered over a pad of Celite and evaporated to give the crude 
amine as grey oil. The material should be immediately used without purification for the 
next-step reaction since both prolonged storage at room temperature and flash 
chromatography would facilitate lactam formation.   
To a solution of the above amine (~9.15 mmol) in anhydrous dichloromethane 
(90 mL) cooled in an ice bath was added N,N-diisopropylethylamine (2.80 mL, 16.07 
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mmol) dropwise, followed by a solution of propargyl chloroformate (1.34 mL, 13.18 
mmol) in dichloromethane (10 mL) dropwise over 20 min. The mixture was then stirred 
at room temperature for 12 h, and it was washed with sodium hydroxide solution (0.5 N, 
20 mL) and brine (20 mL × 2), dried (Na2SO4), evaporated, and flash chromatographed 
(EtOAc/hexanes, 1:3) to give 9 (2.47 g, 79% for two steps) as colorless oil. Rf = 0.28 
(EtOAc/hexanes, 1:2); [α]D20 +3.9 (c 4.96, CH2Cl2); 1H NMR (CDCl3, 500 MHz) δ 5.16 
(d, 1 H, J = 8.5 Hz), 5.12 (t, 1 H, J = 5.8 Hz), 4.62 (d, 2 H, J = 2.5 Hz), 4.26-4.21 (m, 1 
H), 3.14 (dt, 2 H, J = 6.5, 6.5 Hz), 2.45 (t, 1 H, J = 2.2 Hz), 1.80-1.73 (m, 1 H), 1.64-
1.57 (m, 1 H), 1.53-1.44 (m, 2 H), 1.40 (s, 9 H), 1.36-1.30 (m, 2 H); 13C NMR (CDCl3, 
125 MHz) δ 173.4, 155.7, 155.6, 80.0, 78.4, 74.7, 53.2, 52.4, 40.7, 32.3, 29.3, 28.4, 22.4; 
HRMS (ESI) calcd for C16H27N2O6 ([M + H]+) 343.1869, found 343.1871.    
4.2.1.4 N-ε-Propargyloxycarbonyl-L-lysine hydrochloride (2)119 
To a solution of 9 (2.46 g, 7.18 mmol) in THF (30 mL) was added lithium 
hydroxide solution (0.5 M, 30.0 mL, 15.0 mmol), and the mixture was stirred at room 
temperature for 2 h. The mixture was diluted in water (20 mL) and extracted with ether 
(30 mL × 2). The ether extracts were discarded, and the remaining aqueous solution was 
adjusted to pH 3 with hydrochloric acid (3 N), with the concomitant formation of white 
precipitate. The suspension was extracted with ethyl acetate (60 mL × 2), and the 
combined organic phases were washed once with brine (30 mL), dried (Na2SO4), and 
evaporated to give the crude carboxylic acid as colorless oil, which was used without 
further purification.  
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The above crude acid (~7.18 mmol) was dissolved in 1,4-dioxane (20 mL), and 
hydrogen chloride in 1,4-dioxane (4.0 M, 17.0 mL, 68.0 mmol) was added. The resulting 
white suspension was stirred at room temperature for 20 h, filtered, washed with 
dichloromethane, and dried to give 2 (1.44 g, 76% for two steps) as white solid. [α]D22 
+15.7 (c 1.26, 3 N HCl); 1H NMR (D2O, 500 MHz) δ 4.67 (s, 2 H), 4.04 (t, 1 H, J = 6.5 
Hz), 3.16 (t, 2 H, J = 7.0 Hz), 2.90 (s, 1 H), 2.04-1.89 (m, 2 H), 1.57 (quintet, 2 H, J = 
7.1 Hz), 1.53-1.38 (m, 2 H); 13C NMR (D2O, 125 MHz) δ 173.0, 158.3, 79.2, 76.2, 53.6, 
53.3, 40.5, 30.0, 28.9, 22.0; HRMS (ESI) calcd for C10H17N2O4 ([M + H]+) 229.1188, 
found 229.1193. The characterization data matched well with that of the corresponding 
trifluoroacetic acid salt of 2.119  
4.2.1.5  N-α-Boc-N-ε-cyclopentyloxycarbonyl-L-lysine methyl ester (10) 
Compound 8 (2.23 g, 5.65 mmol) was converted into the corresponding amine by 
hydrogenolysis, which was then treated with cyclopentyl chloroformate (1.01 g, 6.79 
mmol) according to the procedure for 9 to give 10 (1.12 g, 53% for two steps) as white 
solid. Rf = 0.35 (EtOAc/hexanes, 1:2); [α]D22 +3.8 (c 1.20, CH2Cl2); 1H NMR (CDCl3, 
500 MHz) δ 5.13 (d, 1 H, J = 7.5 Hz), 5.06 (bs, 1 H), 4.71 (bs, 1 H), 4.28-4.24 (m, 1 H), 
3.72 (s, 3 H), 3.14 (dt, 2 H, J = 6.3, 6.3 Hz), 1.82-1.76 (m, 3 H), 1.66-1.64 (m, 5 H), 
1.55-1.44 (m, 4 H), 1.42 (s, 9 H), 1.39-1.29 (m, 2 H); 13C NMR (CDCl3, 125 MHz) 
δ 173.5, 156.8, 155.6, 80.0, 53.3, 52.4, 40.5, 32.94, 32.93, 32.5, 29.6, 28.5, 23.8, 22.6; 
HRMS (ESI) calcd for C18H33N2O6 ([M + H]+) 373.2339, found 373.2343.    
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4.2.1.6 N-ε-Cyclopentyloxycarbonyl-L-lysine hydrochloride (3) 
According to the same procedure for 2, 10 (1.06 g, 2.84 mmol) afforded 3 (0.71 
g, 85% for two steps) as a white solid. [α]D22+15.0 (c 1.14, 3 N HCl)123 [α]D24 +13.0 (c 
2.0, 80% acetic acid) for the corresponding free amino acid); 1H NMR (D2O, 500 MHz) 
δ 4.94 (m, 1 H), 3.67 (t, 1 H, J = 6.2 Hz), 3.06 (t, 2 H, J = 7.0 Hz), 1,87-1.75 (m, 4 H), 
1.62 (m, 4 H), 1.54-1.51 (m, 2 H), 1.48 (quintet, 2 H, J = 7.0 Hz), 1.39-1.29 (m, 2 H); 
13C NMR (D2O, pH = 10, 125 MHz) δ 183.8, 159.5, 79.4, 56.5, 40.7, 34.7, 32.9, 29.5, 
23.8, 22.8; HRMS (ESI) calcd for C12H23N2O4 ([M + H]+) 259.1658, found 259.1650.  
4.2.1.7 5-(Propargyloxycarbonylamino) fluorescein (6)121 
To a solution of fluoresceinamine isomer I (11, 0.102 g, 0.29 mmol) (Aldrich) in 
anhydrous pyridine (1.0 mL) cooled in an ice bath was added propargyl chloroformate 
(58 µL, 0.59 mmol) dropwise, and the mixture was stirred at room temperature for 30 h. 
Ethyl acetate (50 mL) was then added, and the solution was washed with water (10 mL), 
saturated sodium bicarbonate (10 mL), hydrochloric acid (1 N, 10 mL) and brine (10 
mL), dried (Na2SO4), evaporated, and flash chromatographed (EtOAc/hexanes, 1:1) to 
give yellow oil, which was dissolved in a minimal amount of ethyl acetate (~0.5 mL) 
and precipitated with excessive hexanes (~10 mL) to afford 6 (66 mg, 52%) as bright 
orange solid. Rf = 0.55 (EtOAc/hexanes, 2:1); 1H NMR (CD3OD, 500 MHz) δ 8.17 (s, 1 
H), 7.76 (dd, 1 H, J = 8.5, 2.0 Hz), 7.13 (d, 1 H, J = 9.0 Hz), 6.67 (d, 2 H, J = 2.5 Hz), 
6.65 (d, 2 H, J = 9.0 Hz), 6.54 (dd, 2 H, J = 8.5, 2.5 Hz), 4.82 (d, 2 H, J = 2.5 Hz), 2.97 
(t, 1 H, J = 2.5 Hz); 13C NMR (CD3OD, 75 MHz) δ 171.6, 162.3, 155.0, 154.6, 142.3, 
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130.5, 126.7, 126.2, 114.9, 114.1, 111.9, 103.6, 79.2, 76.4, 53.6; HRMS (ESI) calcd for 
C24H16NO7 ([M + H]+) 430.0927, found 430.0931.   
4.2.2 Construction of plasmids 
All the plasmid structures have been confirmed by DNA sequencing. All 
oligonucleotide primers were purchased from Integrated DNA Technologies, Inc. 
pAcKRS-pylT-GFP1Amber was used as template. In order to test the feasibility of all 
stop codons and one four base codon TAGA, pylT and mutations were introduced to 
both anticodon of pylT and gene of GFP1Amber, corresponding to afford pAcKRS-
pylT-GFP1Ochre, pAcKRS-pylT-GFP1Opal, and pAcKRS-pylT-GFP1four base. In 
addition to check the suppression rate of two codons, another mutation was introduced to 
pAcKRS-pylT-GFP1Ochre to afford pAcKRS-pylT-GFP1TAG149TAA. In this 
plasmid, the tRNA was pylTUUA, which recognized Ochre codon. Two stop codons were 
introduced into GFP, TAG at third position following first Met and second Ala, TAA at 
149th position. pEVOL, carrying two copy of MjTyrRS mutants, was used to suppress 
TAG Amber codon (Figure 53). 
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Figure 53. Plasmid maps of (A) pEVOL and (B) pPylRS-pylT-GFP1TAG149TAA. 
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4.2.2.1 DNA and protein sequences 
pylTCUA: 
5’-ggaaacctgatcatgtagatcgaatggactctaaatccgttcagccgggttagattcccggggtttccgcca-3’ 
pylTUUA: 
5’-ggaaacctgatcatgtagatcgaatggactttaaatccgttcagccgggttagattcccggggtttccgcca-3’ 
pylTUCA: 
5’-ggaaacctgatcatgtagatcgaatggacttcaaatccgttcagccgggttagattcccggggtttccgcca-3’ 
pylTUCUA: 
5’-ggaaacctgatcatgtagatcgaatggacttctaaatccgttcagccgggttagattcccggggtttccgcca-3’  
GFP1TAG149TAA: 
5’-atggcatagagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaa 
ttttctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttc
catggccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaaga
gtgccatgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagt
ttgaaggtgatacccttgttaatcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgagt
acaactataactcacactaagtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaaca
ttgaagatggatccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccatt
acctgtcgacacaatctgccctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctggg
attacacatggcatggatgaactctacaaagagctccatcaccatcaccatcactga-3’ 
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GFP1TAG149TAA (X and X* are the incorporated noncanonical amino acids): 
MAXSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGK
LPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGN
YKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHX*VYITADKQK
NGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNE
KRDHMVLLEFVTAAGITHGMDELYKELHHHHHH 
4.2.2.2 Construction of pAcKRS-pylT-GFP1Ochre, pAcKRS-pylT-GFP1Opal, and 
pAcKRS-pylT-GFP1four base 
pAcKRS-pylT-GFP1Opal contains genes encoding AcKRS, pylTUCA and GFPUV 
with an opal mutation at position 149. This plasmid was derived from pAcKRS-pylT-
GFP1Amber.124 The standard QuikChange site-directed mutagenesis was used to mutate 
the anticodon of pylT in pAcKRS-pylT-GFP1Amber to UCA first. The resulting plasmid 
then underwent the second QuikChange site-directed mutagenesis to mutate TAG at 
position 149 of GFPUV to TGA.   
Similarly, two sequential QuikChange site-directed mutagenesis experiments 
were carried out to mutate the anticodon of pylT and the amber mutation of GFPUV in 
pAcKRS-pylT-GFP1Amber to form pAcKRS-pylT-GFP1Ochre and pAcKRS-pylT-
GFP1four base. 
4.2.2.3 Construction of pAcKRS-pylT-GFP1TAG149TAA 
The plasmid pAcKRS-pylT-GFP1TAG149TAA was derived from pAcKRS-
pylT-GFP1Ochre that contains pylTUUA and GFPUV with an ochre mutation at position 
149 (GFP1Ochre). GFP1TAG149TAA was first generated by PCR amplification of 
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GFP1Ochre with primers that add one amber mutation at the first codon, two additional 
codons (ATGGCA) in front of the first codon, and TGA stop codon at the end of the 
gene. This gene was then cloned into the pAcKRS-pylT-GFP1Ochre between NdeI and 
KpnI sites to afford pAcKRS-pylT-GFP1TAG149TAA. In the final plasmid, GFP1Ochre 
was replaced by GFP1TAG149TAA. 
4.2.2.4 Construction of pPylRS-pylT-GFP1TAG149TAA 
The plasmid pPylRS-pylT-GFP1TAG149TAA was derived from pAcKRS-pylT-
GFP1AG149TAA. The PylRS gene flanked by the constitutive glutamine promoter at 
the 5’ end and the glutamine terminator at the 3’ end was PCR amplified from pBK-
PylRS. Two restriction sites, ClaI at the 5’ end and Hind111 at the 3’ end, were 
introduced in the synthesized DNA, which was subsequently digested by these two 
enzymes and cloned into pAcKRS-pylT-GFP1AG149TAA to replace AcKRS.  
4.2.2.5 Construction of pEVOL-sTyrRS 
The plasmid pEVOL-sTyrRS was derived from pEVOL-AzFRS.125 sTyrRS was 
PCR amplified from pBK-sTyrRS.104 It was then cloned into Nde1and Pst1 sites of 
pEVOL-AzFRS to replace the first AzFRS copy. After confirmation by DNA 
sequencing, the second sTyrRS copy was cloned into Bgl11 and Pst1 sites to replace the 
second copy of AzFRS to afford pEVOL-sTyrRS. 
4.2.3 Orthogonality test  
We attempted to combine the PylRS-pylT pair and the MjTyrRS-  pair 
to incorporate two different NAAs into a single protein because of their proven 
efficiency in NAA incorporation.87, 100, 117, 118, 126-129 In order to use both pairs in a single 
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E. coli cell, we first demonstrated that they were orthogonal to each other. When 
coexpressed in E. coli, either one of the aaRSs could not efficiently charge tRNACUA 
from the other pair with its cognate amino acid (BocK for PylRS87 and L-tyrosine for 
MjTyrRS) to suppress an amber mutation at position 112 of a chloramphenicol 
acetyltransferase gene to give detectable chloramphenicol resistance.  
To test the interaction between PylRS and , two plasmids, pBK-
pylRS and pREP, were used to transform E. coli Top10 cells. pREP contains genes 
encoding  and a chloramphenicol acetyltransferase with an amber mutation at 
position 112. The transformed cells were grown on LB plates containing 25 µg/mL 
kanamycin and 12 µg/mL tetracycline. Five single colonies from the 
kanamycin/tetracycline plate were transferred onto a LB plate containing 25 µg/mL 
kanamycin, 12 µg/mL tetracycline, 34 µg/mL chloramphenicol, and 1 mM BocK. None 
of them were viable. A similar experiment was carried out to test the interaction between 
MjTyrRS and pylT. pBK-JYRS that contains wild type MjTyrRS and pREP in which 
 was replaced with pylT were used to transform E. coli Top10 cells. The 
growth of the transformed cells on a LB plate containing 25 µg/mL kanamycin, 12 
µg/mL tetracycline and 34 µg/mL chloramphenicol did not lead to any viable clones 
(Figure 54).  
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Figure 54. Orthogonality test. 
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4.2.4 Codon suppression test 
We then tested whether we can use mutated pylT to suppress other blank codons. 
Although naturally encoded by the UAG codon, it has been reported that pyrrolysine is 
not hardwired for cotranslational insertion at UAG codon positions.73 The crystal 
structure of the PylRS-pylT complex also revealed no direct interaction between PylRS 
and the anticodon region of pylT.64 We suspected that mutation of the anticodon of pylT 
might not affect its interaction with PylRS and the mutated PylRS-pylT pair could be 
used to suppress a blank codon such as opal UGA codon, ochre UAA codon or even a 
four-base codon UAGA. A pAcKRS-pylT-GFP1Amber plasmid from our previous 
work120, 130 was employed. This plasmid contains genes coding a mutant PylRS 
(AcKRS) specific for AcK, pylT and GFPUV. The GFPUV gene has one amber mutation 
at position 149. Growing cells transformed with this plasmid in LB medium 
supplemented with 5 mM AcK led to full-length GFPUV expression that was easily 
detected by fluorescent emission of GFPUV when excited (Figure 55). When the 
anticodon of pylT was mutated to the complimentary one for opal, ochre or a four-base 
UAGA codon and the corresponding codon was introduced to position 149 of GFPUV in 
the pAcKRS-pylT-GFP1Amber plasmid, cells transformed with the plasmid and grown 
in LB medium supplemented with 5 mM AcK also exhibited detectable GFPUV 
expression for all three mutated pylTs (Figure 55). In comparison to wild-type pylT, 
pylTUUA that suppresses ochre codon gave significantly high suppression levels. This 
indicates that the PylRS-pylTUUA pair can be used to efficiently incorporate NAAs into 
proteins at its corresponding suppressed codons and it might also be feasible to couple 
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the PylRS-pylTUUA pair together with an evolved MjTyrRS- pair to 
incorporate two different NAAs into a single protein in E. coli by both amber and ochre 
suppressions.  
E. coli BL21 cells transformed with pAcKRS-pylT-GFP1Amber were grown in 5 
mL of LB medium at 37 degree overnight, and the culture was subsequently inoculated 
into 50 mL of LB supplemented with 100 µg/mL ampicillin. The expression of GFPUV 
was then induced with the addition of 500 µg/mL IPTG and 1 mM AcK when the OD600 
reached 0.6. After induction, the culture was let grown at 37 degree for 6 h. Cells were 
then harvested by centrifugation at 4500 r.p.m. for 20 min at 4 degree and resuspended 
in 20 mL of lysis buffer (50 mM HEPES, 500 mM NaCl, 10 mM DTT, 10% glycerol, 
0.1% Triton X-100, 5 mM imidazole, and 1 µg/mL lysozyme, pH 7.4). The resuspended 
cells were sonicated in ice water bath three times (4 min each, 5 min interval to cool the 
suspension below 10 degree before the next run) and the lysate was clarified by 
centrifugation at 10200 r.p.m. for 60 min at 4 degree. More lysis buffer was added to the 
supernatant to make a final volume of 50 mL. The expression of GFPUV from cells 
transformed with pAcKRS-pylT-GFP1Amber, pAcKRS-pylT-GFP1Opal, pAcKRS-
pylT-GFP1Ochre and pAcKRS-pylT-GFP1four base were carried out following exactly 
the same procedures. Fluorescence spectroscopic studies of the final clarified GFPUV 
solution were performed on a Cary Eclipse fluorometer. The slit width was 5 nm for 
both excitation and emission. The fluorescence of each sample was excited at 397 nm 
and then measured at 505 nm. 
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Figure 55. Suppression levels of UAG and UAA mutations at position 149 of GFPUV by 
their corresponding mutant pylT suppressors.  
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4.2.5 Expression of wild-type GFPUV 
A pREP plasmid that contains wild type GFPUV gene under control of the T7 
promoter was transformed into BL21 cells. The transformed cells were grown in 5 mL of 
LB medium supplemented with 12 µg/mL tetracycline at 37 °C overnight, and the 
culture was inoculated into 200 mL of LB medium containing 12 µg/mL tetracycline and 
let grown at 37 degree for 8 h. Cells were then harvested by centrifugation at 4500 r.p.m. 
for 20 min at 4 degree and resuspended in 20 mL of lysis buffer (50 mM HEPES, 500 
mM NaCl, 10 mM DTT, 10% glycerol, 0.1% Triton X-100, 5 mM imidazole, and 1 
µg/mL lysozyme, pH 7.4). The resuspended cells were sonicated in ice water bath three 
times (4 min each, 5 min interval to cool the suspension below 10 degree before the next 
run) and the lysate was clarified by centrifugation at 10200 r.p.m. for 60 min at 4 degree. 
The supernatant that contained high concentration of GFP was then fractionated by the 
addition of 70% ammonium sulfate to effect precipitation. The precipitate was then 
redissolved in 100 mM sodium phosphate buffer (pH 7.6) to make a 4 mg/mL solution, 
which was directly used for protein labeling assay. 
4.2.6 Expression and purification of GFPUV(1+4), GFPUV(2+4), GFPUV(3+4) from 
cells transformed with  pPylRS-pylT-GFP1TAG149TAA and pEVOL-AzFRS 
In order to demonstrate the utility of the PylRS-pylTUUA pair together with an 
evolved MjTyrRS-  pair to incorporate two different NAAs into a single 
protein in E. coli by both amber and ochre suppressions, two plasmids, pEVOL-AzFRS 
and pPylRS-pylT-GFP1TAG149TAA, were used to transform E. coli BL21 cells. The 
pEVOL-AzFRS plasmid contains genes encoding an optimized  and two 
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copies of an evolved MjTyrRS (AzFRS) specific for p-azido-L-phenylalanine (4 in 
Figure 56). This plasmid provides an enhanced amber suppression in E. coli.131 The 
pPylRS-pylT-GFP1TAG149TAA plasmid contains genes encoding wild-type M. mazei 
PylRS, pylTUUA, and GFPUV. The GFPUV gene has an amber mutation at position 1, an 
ochre mutation at 149, an N-terminal Met-Ala leader dipeptide in front of the amber 
mutation and an opal stop codon at the C-terminal end.  
 
 
 
 
Figure 56. Chemical structure for compound 1, 2, 3 and 4. 
 
 
E. coli BL21 cells transformed with pPylRS-pylT-GFP1TAG149TAA together 
with pEVOL-AzFRS were grown in 2YT medium (50 mL) at 37 degree overnight. The 
culture was inoculated into 2YT medium (150 mL) containing 100 µg/mL ampicillin and 
25 µg/mL kanamycin and then induced with the addition of 500 µg/mL IPTG and 0.02% 
arabinose when the OD600 reached 0.6. Compound 4 with either one of 1, 2, and 3 were 
added so that there was 1 mM each of the two NAAs. The culture was then incubated at 
37 degree for 8 h, and cells were harvested and lysed as described above. The 
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supernatants were loaded onto a GE Healthcare AKTApurifier UPC 10 FPLC system 
equipped with a Ni-NTA agarose (Qiagen Inc.) column. The column was washed with 5 
× bed volumes of buffer A (50 mM HEPES, 300 mM NaCl and 5 mM imidazole, pH 
7.5) and then eluted by running a gradient from 100% buffer A to 100% buffer B (50 
mM HEPES, 300 mM NaCl and 50 mM imidazole, pH 7.5) in 10 × bed volumes. The 
eluted proteins were concentrated by Amicon Ultra-4 Centrifugal Filter Units (Millipore, 
NMWL 10 KDa) and analyzed by 12% SDS-PAGE. The protein concentrations were 
determined by BCA assay kit, which is purchased from Pierce Inc. 
Growing the transformed cells in 2YT medium supplemented with 1 mM BocK 
(1 in Figure 57A) and 1 mM 4 afforded full-length GFPUV with a yield of 11 mg/L 
(Figure 57B, lane 1). No cellular toxicity due to strong amber and ochre suppressions 
was observed. Exclusion of either NAA from the medium led to no detectable full-length 
GFPUV expression (Figure 57B, lanes 4 & 7). The results indicate that the suppressions 
of amber and opal mutations are dependent on the presence of their corresponding 
NAAs. The ESI-MS of the purified full-length GFPUV incorporated with 4 at position 1 
and 1 at position 149 (GFPUV(1+4)) confirmed the expected incorporations (Figure 58). 
The detected mass (28085 Da) agrees within 70 parts per million with the calculated 
mass (28083 Da) of full-length GFPUV(1+4) without N-terminal methionine. The 
cleavage of N-terminal methionine from expressed GFPUV in E. coli has been observed 
in related studies.89, 120 A mass peak (28059 Da) that is 26 Da smaller than the major 
peak is probably due to the decomposition of the azide group in 4 to form the 
 114 
corresponding amine during ESI-MS analysis, which has been observed previously.132, 
133  
 
 
 
 
Figure 57. (A) Structures of four NAAs. (B) The expression level of full-length GFPUV 
with amber mutation at position 1 and ochre mutation at position 149 from cells 
transformed with pEVOL-AzFRS and pPylRS-pylT-GFP1TAG149TAA at different 
conditions. All NAAs supplemented into media were at 1 mM. 
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Figure 58. ESI spectrum and deconvoluted MS spectrum of GFPUV(1+4). 
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Since wild-type PylRS also charges pylT with Ν-ε-propargyloxycarbonyl-L-
lysine87, 134 (2 in Figure 57A) and N-ε-cyclopentyloxycarbonyl-L-lysine87, 134 (3 in Figure 
56A), the incorporation of either of these two NAAs together with 4 into GFPUV was 
also tested in cells transformed with pEVOL-AzFRS and pPylRS-pylT-
GFP1TAG149TAA. Growing cells in 2YT medium supplemented with 1 mM 2 (or 3) 
and 1 mM 4 afforded full-length GFPUV in good yields (Figure 57B). No full-length 
GFPUV expression was detected when only one NAA was present in the medium. ESI-
MS analysis of the purified proteins confirmed the expected incorporations (GFPUV 
incorporated with 4 and 2 (GFPUV(2+4)): 28065 Da (calculated), 28067 Da (detected) 
(Figure 59). GFPUV incorporated with 4 and 3 (GFPUV(3+4)): 28095 Da (calculated), 
28096 Da (detected)) (Figure 60). 
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Figure 59. ESI spectrum and deconvoluted MS spectrum of GFPUV(2+4). 
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Figure 60. ESI spectrum and deconvoluted MS spectrum of GFPUV(3+4). 
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4.2.7 Protein Labeling 
Since GFPUV(2+4) contains both an alkyne group and an azide group, we tested 
the feasibility of separately labeling this protein with different fluorescent dyes by 
performing click reactions on these two functional groups.119, 135 The reaction of 
GFPUV(2+4) with 3-azido-7-hydroxycoumarin119, 135 in the presence of a Cu(I) 
catalyst119, 135 led to a labeled GFPUV that emitted strong blue fluorescence under long 
wavelength UV light (365 nm) after the protein was denatured and analyzed in a SDS-
PAGE gel (Figure 61, lane 2). The same labeling reaction between wild-type GFPUV 
(wtGFPUV) did not give any detectable blue fluorescence when excited. Since both 
proteins were denatured prior to SDS-PAGE analysis, the endogenous fluorophore of 
GFPUV was quenched and did not interfere with the analysis. The similar click chemistry 
reaction was also carried out between GFPUV(2+4) and a propargyl-conjugated 
fluorescein. The labeled protein emitted strong green fluorescence when excited at 365 
nm (Figure 61, lane 4). The control reaction on wtGFPUV again yielded no detectable 
fluorescently labeled protein (Figure 61, lane 3). These experiments demonstrate that 
both side-chain functional groups of 2 and 4 are active after their incorporation into 
proteins and can be used separately to effect site-specific protein modifications. Since a 
large excess of 5 or 6 relative to the protein were used during labeling experiments, the 
self-coupling reaction between the azide and alkyne groups from two GFPUV(2+4) 
molecules was prevented. No GFPUV(2+4) dimer was observed after the reactions.  
GFPUV(2+4) in 100 mM sodium phosphate buffer (pH 7.6) was concentrated to 4 
mg/mL. To an aqueous sodium ascorbate solution (100 mM, 6 µL, 0.6 µmol) was added  
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Figure 61. Labeling wtGFPUV and GFPUV(2+4) with 5 and 6. The top panel shows 
Coomassie blue stained proteins in a SDS-PAGE gel. The bottom panel shows 
fluorescent imaging of the same gel under UV light (365 nm). The image shows real 
colors captured by a regular camera. The faint top left protein band was due to the partial 
precipitation of wtGFPUV during the labeling reaction. 
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aqueous sulfonated bathophenanthroline sodium salt solution (100 mM, 8 µL, 0.8 µmol) 
followed by copper sulfate (100 mM, 5 µL, 0.5 µmol), and the mixture was incubated at 
room temperature for 5 min. Compound 5 (10 mM in CH2Cl2, 20 µL, 0.2 µmol) or 6 (10 
mM in CH2Cl2, 20 µL, 0.2 µmol) was deposited in a 0.5 mL centrifuge tube and the 
solvent was evaporated by gentle air blowing. GFPUV(2+4) (4 mg/mL, 10 µL, 1.4 nmol) 
was then added, followed by the addition of the above catalyst (2 µL each). Mixture was 
reacted at 4 was reacted at 4 degree for 2 h to give clear solution which was then directly 
loaded onto 12% SDS-PAGE for analysis.  
4.2.8 Expression and purification of GFPUV(4+12) and GFPUV(2+13) 
To generalize the method, we tested the feasibility of using other evolved PylRS-
pylTUUA and  MjTyrRS-  pairs to genetically incorporate their cognate NAAs 
into one protein in E. coli. We replaced the PylRS gene in the pPylRS-pylT-
GFP1TAG149TAA plasmid with the AcKRS gene100 and then transformed E. coli BL21 
cells with the modified plasmid together with pEVOL-AzFRS. Growing the transformed 
cells in 2YT medium supplemented with 1 mM 4 and 5 mM AcK led to full-length 
GFPUV expression with a yield of 6.4 mg/L (Figure 62). Similarly we also replaced 
AzFRS in the pEVOL-AzFRS with an evolved MjTyrRS (sTyrRS)104 that is specific for 
O-sulfo-L-tyrosine (sTyr) and used the resulting plasmid and pPylRS-pylT-
GFP1TAG149TAA to transform E. coli BL21 cells. Growing cells in 2YT medium 
supplemented with 1 mM sTyr and 1 mM 2 led to full-length GFPUV expression with a 
yield of 0.4 mg/L (Figure 62). The low GFPUV expression yield in this case is likely due 
to the low efficiency of the evolved sTyrRS.104 In both cases, no full-length GFPUV was 
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expressed when only one NAA was provided in the media. These results indicate that 
our method can be generally applied to combine any two evolved PylRS-pylTUUA and 
MjTyrRS-  pairs to genetically incorporate their cognate NAAs into a single 
protein in E. coli.  
GFPUV incorporated with 4 at position 1 and 12 at position 149 (GFPUV(4+12); 
12: AcK) and GFPUV incorporated with 13 at position 1 and 2 at position 149 
(GFPUV(2+13); 13: sTyr) were expressed by using two other sets of plasmids. 
GFPUV(4+12) was expressed in E. coli BL21 cells transformed with pAcKRS-pylT-
GFP1TAG149TAA together with PEVOL-AzFRS. The transformed cells were grown in 
2YT medium (50 mL) at 37 degree overnight, and the culture was subsequently 
inoculated into 150 mL of 2YT containing 100 µg/mL ampicillin and 25 µg/mL 
kanamycin. The GFPUV expression was induced with the addition of 500 µg/mL IPTG, 
0.02% arabinose, 1 mM 4, and 5 mM 12 when the OD600 reached 0.6. The culture was 
then let grown at 37 degree for 8 h. Cells were harvested and the proteins were purified 
using the same procedures as described above. GFPUV(2+13) was similarly expressed in 
E. coli BL21 cells transformed with pPylRS-pylT-GFP1TAG149TAA together with 
PEVOL-sTyrRS in the presence of 1 mM 2 and 2 mM 13.  
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Figure 62. (A) Expression yield for GFPUV(4+12) and GFPUV(2+13). (B) SDS-PAGE 
gel, (C) structure of AcK (12) and (D) structure of sTyr (13). Staining was effected by 
Coomassie blue.  
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4.2.9 Unpublished data 
4.2.9.1 DNA and protein sequences of sfGFP 
DNA sequence: 
5’-atggttcatcatcatcatcatcatagcaaaggtgaagaactgtttaccggcgttgtgccgattctggtggaactggatggtga 
tgtgaatggccataaatttagcgttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccctgaaatttatttgcacc
accggtaaactgccggttccgtggccgaccctggtgaccaccctgacctatggcgttcagtgctttagccgctatccggatcata
tgaaacgccatgatttctttaaaagcgcgatgccggaaggctatgtgcaggaacgtaccattagcttcaaagatgatggcaccta
taaaacccgtgcggaagttaaatttgaaggcgataccctggtgaaccgcattgaactgaaaggtattgattttaaagaagatggc
aacattctgggtcataaactggaatataatttcaacagccataatgtgtatattaccgccgataaacagaaaaatggcatcaaagc
gaactttaaaatccgtcacaacgtggaagatggtagcgtgcagctggcggatcattatcagcagaataccccgattggtgatgg
cccggtgctgctgccggataatcattatctgagcacccagagcgttctgagcaaagatccgaatgaaaaacgtgatcatatggt
gctgctggaatttgttaccgccgcgggcattacccacggtatggatgaactgtataaaggcagc-3’ 
Protein sequence: 
MVHHHHHHSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKF
ICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISF
KDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITA
DKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLS
KDPNEKRDHMVLLEFVTAAGITHGMDELYKGS 
4.2.9.2 Plasmids introduction 
pBAD-sfGFP134TAG: Plasmid pBAD-sfGFP134TAG that has a sequence-
optimized superfolder GFP (sfGFP) gene with an amber mutation at N134 and a 6 × His 
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tag at its C terminus was a kind gift from Dr. Ryan Mehl of Franklin & Marshall 
College.  
pETtrio-pylT(UUA)-PylRS-MCS: This plasmid was derived from pPylRS-pylT-
GFP1TAG149TAA and contains a  gene (a C34U form of ) under 
control of the lpp promoter and the rrnC terminator, the wild type Methanosarcina 
mazei PylRS gene under control of the glnS promoter and terminator, and multiple 
cloning sites under control of the T7 promoter and terminator.  
Three plasmids that vary at anticodon of tRNAPyl and have different nonsense 
mutations at N134 of the sfGFP gene were derived from pETtrio-pylT(UUA)-PylRS-
sfGFP134TAG. Constructions of these plasmids were carried out using a site-directed 
mutagenesis protocol that was based on Phusion DNA polymerase. In brief, two 
oligonucleotide primers, one of which covers the mutation site and contains mutagenized 
nucleotides were used to amplify the whole plasmid of pETtrio-pylT(UUA)-PylRS-
sfGFP134TAG to give a blunt-end PCR product. This PCR product was phosphorylated 
by T4 PNK and then ligated to itself using T4 DNA ligase. Primers pylT-F with a 
sequence of 5’-GTC CAT TCG ATC TAC ATG ATC AGG TT-3’ and pylT-TAG-R 
with a sequence of 5’-TCT AAA TCC GTT CAG CCG GGT TAG-3’ were used to 
make pETtrio-pylT(CUA)-PylRS-sfGFP134TAG that has a  gene and a sfGFP 
gene with an amber mutation at N134. Primers sfGFPN134-F with a sequence of 5’-
GGC AAC ATT CTG CAT AAA CTG GA-3’and sfGFPN134TGA-R with a sequence 
of 5’-TTA TTC TTT AAA ATC AAT ACC TTT CAG TTC AAT GC-3’ were used to 
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make pETtrio-pylT(UUA)-PylRS-sfGFP134TAA that has a  gene and a sfGFP 
gene with an ochre mutation at N134. Two set of primers: (1) pylT-F and pylT-TGA-R 
with a sequence of 5’-TTC AAA TCC GTT CAG CCG GGT TAG-3’ and (2) 
sfGFPN134-F and sfGFPN134TGA-R with a sequence of 5’-TCA TTC TTT AAA ATC 
AAT ACC TTT CAG TTC AAT GC-3’ were used to run two consecutive site-directed 
mutagenesis reactions to obtain plasmid pETtrio-pylT(UCA)-PylRS-sfGFP134UGA that 
contains a  gene and a sfGFP gene with a opal mutation at N134. Two sets of 
primers (1) pylT-F and pylT-AGGA-R with a sequence of 5’-TTC CTA ATC CGT TCA 
GCC GGG TTA G-3’ and (2) sfGFPN134-F and sfGFPN134AGGA-R with a sequence 
of 5’-TCC TTT CTT TAA AAT CAA TAC CTT TCA GTT CAA TGC-3’ were also 
used to run two consecutive site-directed mutagenesis reactions on pETtrio-pylT(UUA)-
PylRS-sfGFP134TAG to generate plasmid pETtrio-pylT(UCCU)-sfGFP134AGGA that 
contains a  gene with a quadruple UCCU anticodon and a sfGFP gene with a 
quadruple AGGA mutation at N134.  
4.2.9.3 Amber, opal, and ochre, AGGA suppression analysis of the PylRS-pylT pairs 
To demontrate amber suppression efficiency of the PylRS-  pair, E. coli 
BL21 cells transformed with pETtrio-pylT(CUA)-PylRS-sfGFP134TAG were used to 
express sfGFP in the absence or presence of 5 mM BocK, a substrate of PylRS. Without 
BocK in the growth medium, only basal level expression of full-length sfGFP was 
observed. On the contrary, the addition of BocK promoted the overexpression of full-
length sfGFP (Figure 63). This clearly indicates that the PylRS-pylT pair is an efficient 
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amber suppressing aaRS-tRNA pair and its mediated suppression is dependent on the 
presence of a NAA.  
It has been previously demonstrated that is not hardwired for 
recognizing an amber codon. Mutagenizing the anticodon of  from CUA to 
other triplet anticodons does not significantly alter the acylation potential of  by 
PylRS. As expected, mutating C34 in to U34 in did not significantly 
change the orthogonality of the tRNA.  
Although expected to be orthogonal,  that is a C34U/U35C mutant 
form of  is apparently not orthogonal in E. coli. Cells transformed with 
pETtrio-pylT(UCA)-PylRS-sfGFP134TGA exhibited a very high expression level of 
full-length sfGFP both in the absence and in the presence of BocK in the media (Figure 
63). 
The AGGA suppression is also very interesting. mutant form 
 is apparently not orthogonal in E. coli. Cells transformed with pETtrio-
pylT(UCCU)-PylRS-sfGFP134AGGA exhibited a very high expression level of full-
length sfGFP both in the absence and in the presence of BocK in the media (Figure 64). 
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Figure 63. Suppression of amber, opal, and ochre mutations. Suppression of amber, 
opal, and ochre mutations at N134 of sfGFP by their corresponding suppressing PylRS-
tRNAPyl pairs in the absence and presence of BocK. Proteins shown in the gel represent 
their really expression levels. The first two lanes show sfGFP expression levels in cells 
transformed with pETtrio-PylT(CUA)-PylRS-sfGFP134TAG; the second two lanes 
show sfGFP expression levels in cells transformed with pETtrio-PylT(UCA)-PylRS-
sfGFP134TGA; the last two lane show sfGFP expression levels in cells transformed with 
pETtrio-PylT(UUA)-PylRS-sfGFP134TAA. 
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Figure 64. PylTUCCU is not orthogonal in E. coli. Expression of sfGFP in cells 
transformed with pETtrio-pylT(UCCU)-sfGFP134AGGA and grown in the presence or 
absence of 5 mM BocK.  
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4.3 Summary 
In summary, we have developed a facile system for genetic incorporation of two 
different NAAs at two defined sites of a single protein in E. coli with moderate to high 
protein production yields. This technique will greatly expand the scope of potential 
applications for the genetic NAA incorporation approach, and it can be applied to install 
a FRET pair to a protein for conformation and dynamics studies, synthesize proteins 
with two different post-translational modifications for functional analysis, or generate 
phage-displayed peptide libraries with the expanded diversity of the displayed peptides. 
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5. A STRAIGHTFORWARD ONE PLASMID SELECTION SYSTEM FOR 
EVOLUTION OF AMINOACYL-TRNA SYNTHETASES 
 
5.1 Introduction 
Given the importance of proteins in biology, it’s desirable to be able to 
manipulate proteins for understanding of their structures and functions, such as protein 
folding, protein-protein interactions, protein localization, and protein-involved 
biological processes, etc. The ability to genetically encode NAAs into proteins would 
enable site-specific modification of proteins in vivo and in vitro, thus providing novel 
tool for understanding of protein functions. One of the most popular methods is the 
genetic incorporation of NAAs directly into proteins during translation in living cells, 
which was developed by Schultz et al.76-82 To date, several orthogonal aaRS/tRNA 
pairs, such as evolved MjTyrRS-  and PylRS-pylT pairs, have been 
introduced to live cells to facilitate NAA incorporation. More than 70 NAAs have 
been successfully incorporated into proteins in E. coli.87, 100, 103, 115-119, 136 
To evolve an orthogonal aaRS/tRNA pair in E. coli, the most critical step is the 
redesign and evolution of the amino acid binding pocket of the existed orthogonal 
aaRS. A library of aaRS variants carrying random mutations is subjected to several 
rounds of positive and negative selections. Nowadays, several positive and negative 
selections were developed, such as most commonly used antibiotic resistance genes126, 
greens fluorescence protein137, barnase76, and acetyltransferase/uracil 
phosphoribosyltranserease (cat-uprt) 138.  
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In our previous work, we have been able to develop an evolved pylRS/pylT 
pair, which could specifically take a photocaged N-ε-methyl-L-lysine. To select PylRS 
variants specific for different NAAs in E. coli, we have adopted an existing positive 
and negative selection scheme developed by Schultz et al.103, 126 As shown in Scheme 
4, the positive selection is based on resistance to chloramphenicol, which was 
conferred by the suppression of an amber mutation at a permissive site, Q107, in the 
chloramphenicol acetyltransferase (CAT) gene. PylRS variants can either acylate pylT 
with the NAA or any natural amino acid will grow on the plate with antibiotics 
chloramphenicol. Negative selection utilizes the toxic barnase gene with amber 
mutations at two permissive sites, Q2 and D44, and is carried out in the absence of the 
NAA. Growth in the presence of arabinose leads to the death of cells in which PylRS 
variants can acylate pylT with any natural amino acid. Only PylRS variants that could 
acylate pylT with the NAA but not with the endogenous amino acids could survive 
both selections. Additional cycles of positive and negative selections can be carried 
out to increase the specificity of PylRS variants toward individual NAA (Scheme 4). 
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Scheme 4. Two-Plasmid Selection System 
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Effective as it is, the current selection system has several disadvantages. First, 
the surviving pool of aaRS plasmids must be isolated from selective plasmid after each 
step, and be transformed to the new host cells with high competence. These 
reoccurring plasmid isolation and transformation procedures require significant 
laboratory labor work and resources as well as time investment. Due to the lethalness 
of the negative selection marker barnase, the flexibility of the system is restricted. One 
plasmid selection system using chloramphenicol acetyltransferase/uracil 
phosphoribosyltranserease (cat-uprt) fusion gene was developed by Schutlz et al. 
Herein, we have developed a series of dual positive/negative selection vectors using 
different positive and negative selection markers. 
5.2 Plasmid construction: positive selection marker  
To build a series of dual plasmid, I started with construct the two-plasmid 
selection system. The positive selection marker pY+ (Figure 65) contains an amber 
suppressor tRNA (pylT) and the positive selection marker chloramphenicol 
acetyltransferase (CAT) with an amber stop codon (D112TAG). In the presence of 
chloramphenical (cm) and provided NAA, the positive surviving aaRS variants are 
capable of incorporating either the NAA or endogenous amino acids. 
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Figure 65. Plasmid structure of pY+. 
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5.2.1 Plasmid construction of pY+ 
Plasmid pY+ is used to carry out positive selection. It was derived from 
pRep,115 the gene of tRNACUA for MjTyrRS was replaced by pylT, tRNACUA for 
MmPylRS. The gene of pylT flanked by the lpp promoter at the 5’ end and the rrnC 
terminator at the 3’ end was amplified from pBK-AcKRS-pylT,139 using two 
oligodeoxynucleotide primers (5’-
CCCATCAAAAAAATATTCTCAACATAAAAAACTTTG-3’ and 5’-
CGGGACAGGCTGACAACCCGAGGATCT-3’). pylT-lpp franking gene with 
EcoR1 at the 5’ end was amplified by two oligodeoxyuncleotide primers (5’-
CATCCGGAATTCCGTATGGCAATGAAAG-3’ and 5’-
CCCATCAAAAAAATATTCTCAACATAAAAAACTTTG-3’), using Prep as 
template. pylT-rrnc franking gene with Eagl at the 3’ end was amplified by two 
oligodeoxynucleotide primers (5’-
GGTTGTCAGCCTGTCCCGGCTTGGCACTGGCCGTCG-3’ and 5’-
GCATGGCGGCCGACGCGCTGGGC-3’). Then the gene of pylT that was annealed 
with these two fragments was digested by EcoR1 and Eag1 restriction enzymes, and 
then cloned into the predigested pRep to afford pY+.  
5.3 Plasmid construction: negative selection marker 
The negative selection plasmid, pY-, bears the pylT gene and the barnase gene 
with two amber mutations (Q2TAG and D44TAG). The barnase gene is under control 
of a pBad promoter (Figure 66). The toxicity of negative selection marker eliminates 
the aaRS variants that recognize endogenous amino acids. In the presence of negative 
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selection marker and absence of NAA, the aaRS variants taking endogenous amino 
acids won’t survive.  
5.3.1 Plasmid construction of pY- 
Plasmid pY- is used to do positive selection. It was derived from pNeg,137 the 
gene of tRNACUA for MjTyrRS was replaced by pylT, tRNACUA for MmPylRS. The 
gene of pylT flanked by the lpp promoter at the 5’ end and the rrnC terminator at the 
3’ end was amplified from pBK-AcKRS-pylT, using two oligodeoxynucleotide 
primers (5’-CCCATCAAAAAAATATTCTCAACATAAAAAACTTTG-3’ and 5’-
CGGGACAGGCTGACAACCCGAGGATCT-3’). pylT-rrnc franking gene with Nde1 
at the 5’ end was amplified by two oligodeoxynucleotide primers (5’-
GATATACATATGGCATAGGTTATCAACACG-3’ and 5’-
GTTGTCAGCCTGTCCCGTCGTTTTACAACGTC-3’), using Prep as template. 
pylT-lpp franking gene with Pst1 at the 3’ end was amplified by two 
oligodeoxynucleotide primers (5’-
CCCATCAAAAAAATATTCTCAACATAAAAAACTTTG-3’ and 5’-
CGATGCCTGCAGCAATGGCAACAACGTTG-3’). Then the gene of pylT that was 
annealed with these two fragments was digested by Nde1 and Pst1 restriction 
enzymes, and cloned into the predigested pNeg to afford pY-. 
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Figure 66. Plasmid structure of pY-. 
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5.3.2 DNA and protein sequences of barnaseQ2TAGD44TAG 
DNA sequence: 
5’-atggcataggttatcaacacgtttgacggggttgcggattatcttcagacatatcataagctacctgataattacattacaaa 
atcagaagcacaagccctcggctgggtggcatcaaaagggaaccttgcataggtcgctccggggaaaagcatcggcgga
gacatcttctcaaacagggaaggcaaactcccgggcaaaagcggacgaacatggcgtgaagcggatattaactatacatc
aggcttcagaaattcagaccggattctttactcaagcgactggctgatttacaaaacaacggaccattatcagacctttacaaa
aatcagataa-3’ 
Protein sequence: 
MA*VINTFDGVADYLQTYHKLPDNYITKSEAQALGWVASKGNLA*VAPGKSI
GGDIFSNREGKLPGKSGRTWREADINYTSGFRNSDRILYSSDWLIYKTTDHYQ
TFTKIR 
5.4 Pduel 1: pNeg-barnaseQ2TAGQ3TAGD44TAG-Cm(R) 
In order to simplify the library selection process, we tried to develop a single 
plasmid that contains both positive and negative selection markers. We first took 
advantage of the current positive and positive plasmids, by integrating the positive and 
negative selection markers into pY- plasmid. The first generation of single selection 
plasmid, Pduel 1, bears the pylT gene and the barnase gene with three amber 
mutations (Q2TAG, Q3TAG and D44TAG) and chloramphenicol acetyltransferase 
(CAT) with an amber stop codon (D112TAG) (Figure 67). The reason to put one more 
amber stop codon into barnase is because the toxicity is still too high for effective 
negative selection with two amber codons from previous study. For the positive 
selection, the amber stop codon in CAT will be suppressed in the presence of NAAs or 
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misincorporated natural amino acids. On the contrary, for the negative selection, the 
barnase gene, under the control of pBad, will be expressed and lead to cell death in the 
presence of misincorporated natural amino acids and 0.2% of arabinose. 
5.4.1 Plasmid construction of Pduel 1 
Plasmid Pduel 1 was derived from pY-. BarnaseQ2TAGD44TAG was replaced 
by barnaseQ2TAGQ3TAGD44TAG. BarnaseQ2TAGQ3TAGD44TAG was amplified 
from pY- by two oligodeoxynucleotides (5’-
GGAGATATACATATGGCATAGTAGATCAACACGTTTGAC-3’, and 5’-
AATGGTGCATGCTTATCTGATTTTTGTAAAG-3’). Two restriction sites Nde1 at 
5’ head and Sph1 at 3’ tail were designed into the synthesized DNA that was then 
cloned into pY- digested with Nde1 and Sph1 to make pNeg-
barnaseQ2TAGQ3TAGD44TAG. Cm(R)D112TAG with its promoter and terminator 
was amplified from pY+ by two oligodeoxynucleotides (5’-
GCGGCCAAGCTTTGATGTCCGGCGGTGC-3’, and 5’-
GCGCCAAGCTTACTTATTTTTGATCGTT-3’), and cloned into predigested pNeg-
barnaseQ2TAGQ3TAGD44TAG  by Hind111 at both 5’head and 3’ tail to afford 
Pduel 1.  
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Figure 67. Plasmid structure of Pduel 1. 
 
 
5.4.2 The activity test of Pduel 1 
To demonstrate the system applicability, Pduel 1 was used together with the 
pBK-MmPylRS containing wild-type PylRS gene to transform E. coli Top10 strain. 
For positive selection, the Top 10 cells were let grown on the GMML plates, with 1% 
of glucose, and 0.3 mM leucine. The minimal media GMML was used due to the 
presence of large amount of natural amino acids, which is too rich for positive 
selection. 100 µg/mL of ampicillin and 25 µg/mL of kanamycin were provided to 
force cells containing Pduel 1 and pBK-MmPylRS. 34 µg/mL or 68 µg/mL of 
chloramphenicol were used with and without 1 mM BocK, which could be applied to 
suppress ambor codon by MmPylRS. Without chloramphenicol, cells were healthy. 
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However, in the presence of chloramphenicol and 1 mM BocK, cells were all dead. It 
indicated either the positive selective marker, Cm(R) inside Pduel 1, didn’t function 
well or the negative selective marker, barnase, was too toxic for cells. For the negative 
selection, the Top 10 cells were let grown on LB plates, with 100 µg/mL of ampicillin 
and 25 µg/mL of kanamycin to keep cells maintaining Pduel 1 and pBK-MmPylRS. 
5% of glucose or 0.2% of arabinose was provided, with or without of 1 mM BocK. For 
the Pduel 1, glucose and arabinose were used to inhibit or promote the expression of 
barnase. Without BocK, cells were healthy. With BocK, no matter whether glucose or 
arabinose was present, cells were all dead (Table 3). It indicated the barnase, even with 
three amber codons, was still too toxic. It also interfered with the positive selection, 
leading to the failure of positive selection undetermined. 
 
 
Table 3. Activity Test of Pduel 1 
 
Positive (GMML) 
100 µg/mL amp 
25 µg/mL kan 
0.3 mM Leucine 
1% Glucose + + + 
34 or 68 µg/mL cm - + + 
1 mM BocK - - + 
 Grow Die Die 
Negative (LB) 
100 µg/mL amp 
25 µg/mL kan 
5% Glucose - + - 
0.2% arabinose - - + 
1 mM BocK - + + 
 Grow Die Die 
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5.5 Pduel 2: pNeg-barnaseQ2TAGQ3TAGK27AD44TAG-Cm(R) 
Due to the high toxicity of barnaseQ2TAGQ3TAGD44TAG, another 
modification was made to barnase. The mutation K27A to barnase was reported 
previously to great reduce its toxicity.140 BarnaseQ2TAGQ3TAGK27AD44TAG was 
further made to replace barnaseQ2TAGQ3TAGD44TAG in Pduel 1 to afford pDuel 2 
(Figure 68).  
5.5.1 Plasmid construction of Pduel 2 
Plasmid Pduel 2 was derived from Pduel 1. Using Pduel 1 as template, barnase 
Q2TAGQ3TAGK27AD44TAG was generated by site-directed mutagenesis using four 
oligodeoxynucleotides (5’-
GGAGATATACATATGGCATAGTAGATCAACACGTTTGAC-3’, 5’-
GATAATTACATTACAGCATCAGAAGCACAAGCC-3’, 5’-
GGCTTGTGCTTCTGATGCTGTATGTAATTATC-3’, and 5’-
AATGGTGCATGCTTATCTGATTTTTGTAAAG-3’), and then cloned into digested 
Pduel 1 by two restriction sites Nde1 at 5’ head and Sph1 at 3’ tail to make Pduel 2. 
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Figure 68. Plasmid structure of Pduel 2. 
 
 
 
 
 
 
  
 145 
5.5.2 The activity test of Pduel 2 
Same as Pduel 1, Pduel 2 and pBK-MmPylRS were used to cotransform E. coli 
Top10 strain. For positive selection, the Top 10 cells were let grown on the LB plates, 
with 1% of glucose, 100 µg/mL of ampicillin, and 25 µg/mL of kanamycin. Only 34 
µg of chloramphenicol were used with and without 1 mM BocK. As for the result, 
without chloramphenicol, cells were healthy. In the presence of chloramphenicol and 1 
mM BocK, only a few cells survived. For the negative selection, the Top 10 cells were 
let grown on LB plates. 5% of glucose or 0.2% of arabinose was provided, with or 
without of 1 mM BocK. With or without BocK, cells were survived. With 1 mM BocK 
and 0.2% arabinose, cells were grown but unhealthy (Table 4). It indicated the 
mutation of K29A to barnase, greatly decreased the toxicity of it. The toxicity of 
barnase, with three amber codons and K29A mutation, was too weak to kill cells.  
 
 
  Table 4. Activity Test of Pduel 2 
 
Positive (LB) 
100 µg/mL amp 
25 µg/mL kan 
 
1% Glucose + + + 
34 µg/mL cm - + + 
1 mM BocK - - + 
 Grow Die Die 
Negative (LB) 
100 µg/mL amp 
25 µg/mL kan 
5% Glucose - + - 
0.2% arabinose - - + 
1 mM BocK - + + 
 Grow Grow Grow 
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5.6 Pduel 3: pNeg-barnaseQ2TAGK27AD44TAG-Cm(R) 
Due to the low toxicity of barnaseQ2TAGQ3TAGK27AD44TAG, the Q3TAG 
was mutated back to Q3. Therefore, a new plasmid Pduel 3 was constructed to better 
control the toxicity of barnase (Figure 69).  
5.6.1 Plasmid construction of Pduel 3 
Plasmid Pduel 3 was derived from Pduel 2. Using Pduel 2 as template, 
barnaseQ2TAGK29AD44TAG was amplified by two oligodeoxynucleotides (5’-
GATATACATATGGCATAGGTTATCAACACG-3’, and 5’-
AATGGTGCATGCTTATCTGATTTTTGTAAAG-3’), and then cloned into digested 
Pduel 2 by two restriction sites Nde1 at 5’ head and Sph1 at 3’ tail to make Pduel 3. 
 
 
 
 
Figure 69. Plasmid structure of Pduel 3. 
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5.6.2 The activity test of Pduel 3 
Pduel 3 and pBK-MmPylRS were used to cotransform E. coli Top10 strain. For 
positive selection, the Top 10 cells were let grown on the LB plates, with 1% of 
glucose, 100 µg/mL of ampicillin, and 25 µg/mL of kanamycin. Only 34 µg of 
chloramphenicol were used with and without 1 mM BocK. As for the result, without 
chloramphenicol, cells were healthy. In the presence of chloramphenicol and 1 mM 
BocK, only a few cells survived. For the negative, the Top 10 cells were let grown on 
LB plates. 5% of glucose or 0.2% of arabinose was provided, with or without of 1 mM 
BocK. Without BocK, cells were healthy. With 1 mM BocK and glucose, cells were 
healthy. With 1 mM BocK and 0.2% of arabinose, cells were all dead (Table 5). It 
indicated the toxicity of barnase, with two amber codons and K29A mutation, was 
under good control. It also indicates the inefficiency of positive selection due to the 
positive selective marker itself.  
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Table 5. Activity Test of Pduel 3 
 
Positive (LB) 
100 µg/mL amp 
25 µg/mL kan 
 
1% Glucose + + + 
34 µg/mL cm - + + 
1 mM BocK - - + 
 Grow Die Die 
Negative (LB) 
100 µg/mL amp 
25 µg/mL kan 
5% Glucose - + - 
0.2% arabinose - - + 
1 mM BocK - + + 
 Grow Grow Die 
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5.7 Pduel 4: pRep-barnaseQ2TAGK27AD44TAG 
While the toxicity of barnase in Pduel 3 was under good control, the activity of 
Cm(R)D112TAG did not function appropriately. Since the Cm(R)D112TAG in pY+ 
worked, we decided to use pY+ as new scaffold to generate Pduel 4 plasmid by 
replacing the gene of GFP in pY+ with barnaseQ2TAGK27AD44TAG (Figure 70). In 
the plasmid Pduel 4, for the positive selection, the amber stop codon in CAT will be 
suppressed in the presence of NAAs or misincorporated natural amino acids. On the 
contrary, for the negative selection, the barnase gene, under control of T7 promoter, 
will be produced and kill cells if the T7 polymerase is expressed. In the Pduel 4, T7 
polymerase, with two amber codons, is under the control of pBad promoter. T7 
polymerase will be expressed, and induce the expression of barnase in the presence of 
misincorporated natural amino acids and 0.2% of arabinose. 
5.7.1 Plasmid construction of Pduel 4 
Plasmid Pduel 4 was derived from pY+. The gene of GFP was replaced by 
gene of barnaseQ2TAGK29AD44TAG. Using Pduel 3 as template, barnase 
Q2TAGK29AD44TAG was amplified by two oligodeoxynucleotides (5’-
TTTCCCTCTAGAGAAATAATTTTGTTTAACTTTAAGAAGG-3’, and 5’-
TTTGTAGAGCTCTTATCTGATTTTTGTAAAGGTCTG-3’), and then cloned into 
digested pY+ at two restriction sites Nde1 and Sac1 to make Pduel 4. 
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Figure 70. Plasmid structure of Pduel 4. 
 
 
5.7.2 The activity test of Pduel 4 
Pduel 4 and pBK-MmPylRS were used to cotransform E. coli Top10 strain. 
The Top 10 cells were let grown on the LB plates, with 5% of glucose, 12.5 µg/mL of 
tetracycline, and 25 µg/mL of kanamycin. Only 34 µg of chloramphenicol were used 
with and without BocK. As for the result, without chloramphenicol and BocK, cells 
were healthy. In the presence of chloramphenicol and 0.1, 0.25, 0.5 and 1 mM of 
BocK, no cell was grown. With 0.1 mM BocK, many cells were grown. With 0.25 mM 
of BocK, a few cells were grown. With 0.5 and 1 mM of BocK, no cell was grown 
(Table 6). It indicated 0.25 mM of BocK was not enough to produce barnase to kill all 
cells in the presence of glucose. 0.1 mM of BocK would give lower toxicity of 
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barnase, which mean the activity of barnase inside Pduel 4 was adjustable. However, if 
chloramphenicol was present, no cell could survive. Therefore, we faced the dilemma. 
With high concentration of BocK, the toxicity of barnase would lead to cell death. 
With low concentration of BocK, Cm(R) could not suppress the chloramphenicol, 
which would also cause cell death. This was no way out for efficient positive selection 
at this stage.  
 
 
Table 6. Activity Test of Pduel 4 
 
34 µg/mL cm - + - + - + - + - 
5% Glucose + + + + - - - - - 
0.1 mM BocK + + - - - - - - - 
0.25 mM BocK - - + + - - - - - 
0.5 mM BocK - - - - + + - - - 
1 mM BocK - - - - - - + + - 
 Die Die Die Die Die Die Die Die Grow 
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5.8 Pduel 5: pRep-barnaseQ2TAGQ2TAGK27AD44TAG 
While the toxicity of barnase in Pduel 4 was still too lethal to cells, the 
mutation Q3TAG was added back to barnase to generate Pduel 5 (Figure 71).  
5.8.1 Plasmid construction of Pduel 5 
Plasmid Pduel 5 was derived from Pduel 4. The gene of 
barnaseQ2TAGK29AD44TAG was replaced by gene of 
barnaseQ2TAGQ3TAGK29AD44TAG. Using Pduel 4 as template, barnase 
Q2TAGQ3TAGK29AD44TAG was amplified by two oligodeoxynucleotides (5’-
GGAGATATACATATGGCATAGTAGATCAACACGTTTGAC-3’, and 5’-
TTTGTAGAGCTCTTATCTGATTTTTGTAAAGGTCTG-3’), and then cloned into 
digested pY+ at two restriction sites Nde1 and Sac1 to make Pduel 5. 
5.8.2 The activity test of Pduel 5 
The activity test of Pduel 5 was confusing and therefore was not provided.  
5.9 Pduel 6: pRep-barnaseQ2TAGD44TAG 
Due to the fact that the toxicity of barnase under control of T7 promoter was 
hard to adjust, the T7 polymerase with two amber codons was replaced by the gene of 
barnaseQ2TAGD44TAG (Figure 72). In the plasmid Pduel 6, for the negative 
selection, the barnase gene, under the control of pBad promoter, would be expressed in 
the presence of 0.2% of arabinose and when its amber mutations are suppressed.  
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Figure 71. Plasmid structure of Pduel 5. 
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5.9.1 Plasmid construction of Pduel 6 
Plasmid Pduel 6 was derived from pY+. The gene of T7 polymerase was 
replaced by gene of barnaseQ2TAGD44TAG. Using pY- as template, barnase 
Q2TAGD44TAG was amplified by two oligodeoxynucleotides (5’-
GGCCGGTGCACATGGCATAGGTTATC-3’, and 5’-
CGGCCGACGTCTTATCTGATTTTTGTA-3’), and then cloned into digested pY+ at 
two restriction sites Apal1 and Aat11 to make Pduel 6. 
5.9.2  The activity test of Pduel 6 
Pduel 6 and pBK-mmpylRS were cotransformed into E. coli Top10 strain. For 
positive selection, the Top 10 cells were let grown on the LB plates, 12.5 µg/ml of 
tetracycline and 25 µg/ml of kanamycin. 68 µg/ml of chloramphenicol were used 
together with and without 1 mM BocK. In the presence of chloramphenicol, with 1 
mM BocK, cells all survived; without BocK, cells all died.  However, for the negative 
condition, with 0.2% of arabinose and 1 mM BocK, the suppression was not obvious 
was added (Table 7).  
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Figure 72. Plasmid structure of Pduel 6. 
 
 
Table 7. Activity Test of Pduel 6 
 
Positive (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
68 µg/mL cm - + + 
1 mM BocK - - + 
 Grow Die Grow 
Negative (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
0.2% arabinose - - + 
1 mM BocK - + + 
 Grow Grow Inhibitio
n 
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5.10 Pduel 7: pRep-SacB 
Although we tried very hard, the toxicity of barnase in Pduel was hard to 
adjust. Therefore, we had to choose other negative selective marker, namely SacB. 
The sacB gene encodes the enzyme levansucrase, which catalyzes the formation of 
high molecular weight fructose polymers. The accumulation of these polymers in the 
periplasm interferes with metabolism, and causes cell death. Thus, the sacB gene is 
lethal to a gram-negative cell growing on a medium containing sucrose. Plasmid Pduel 
7 was obtained by replacing the gene of GFP in pY+ with the gene of sacB (Figure 
73). In the plasmid Pduel 6, for the negative selection, the sacB gene, under control of 
T7 promoter, will be produced and cause cell death in the presence of sucrose. T7 
polymerase, with two amber codons, is under the control of pBad promoter. T7 
polymerase will be expressed, and induce the expression of SacB in the presence of 
0.2% of arabinose and when its amber mutations are suppressed. 
5.10.1 DNA and protein sequences of SacB 
DNA sequence: 
5’-atgaacatcaaaaagtttgcaaaacaagcaacagtattaacctttactaccgcactgctggcaggaggcgcaactcaag 
cgtttgcgaaagaaacgaaccaaaagccatataaggaaacatacggcatttcccatattacacgccatgatatgctgcaaatc
cctgaacagcaaaaaaatgaaaaatatcaagttcctgagttcgattcgtccacaattaaaaatatctcttctgcaaaaggcctg
gacgtttgggacagctggccattacaaaacgctgacggcactgtcgcaaactatcacggctaccacatcgtctttgcattagc
cggagatcctaaaaatgcggatgacacatcgatttacatgttctatcaaaaagtcggcgaaacttctattgacagctggaaaa
acgctggccgcgtctttaaagacagcgacaaattcgatgcaaatgattctatcctaaaagaccaaacacaagaatggtcagg
ttcagccacatttacatctgacggaaaaatccgtttattctacactgatttctccggtaaacattacggcaaacaaacactgaca 
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Figure 73. Plasmid Structure of Pduel 7. 
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actgcacaagttaacgtatcagcatcagacagctctttgaacatcaacggtgtagaggattataaatcaatctttgacggtgac
ggaaaaacgtatcaaaatgtacagcagttcatcgatgaaggcaactacagctcaggcgacaaccatacgctgagagatcct
cactacgtagaagataaaggccacaaatacttagtatttgaagcaaacactggaactgaagatggctaccaaggcgaagaa
tctttatttaacaaagcatactatggcaaaagcacatcattcttccgtcaagaaagtcaaaaacttctgcaaagcgataaaaaac
gcacggctgagttagcaaacggcgctctcggtatgattgagctaaacgatgattacacactgaaaaaagtgatgaaaccgct
gattgcatctaacacagtaacagatgaaattgaacgcgcgaacgtctttaaaatgaacggcaaatggtacctgttcactgact
cccgcggatcaaaaatgacgattgacggcattacgtctaacgatatttacatgcttggttatgtttctaattctttaactggcccat
acaagccgctgaacaaaactggccttgtgttaaaaatggatcttgatcctaacgatgtaacctttacttactcacacttcgctgta
cctcaagcgaaaggaaacaatgtcgtgattacaagctatatgacaaacagaggattctacgcagacaaacaatcaacgtttg
cgccaagcttcctgctgaacatcaaaggcaagaaaacatctgttgtcaaagacagcatccttgaacaaggacaattaacagtt
aacaaataa-3’ 
Protein sequence: 
MNIKKFAKQATVLTFTTALLAGGATQAFAKETNQKPYKETYGISHITRHDML
QIPEQQKNEKYQVPEFDSSTIKNISSAKGLDVWDSWPLQNADGTVANYHGYH
IVFALAGDPKNADDTSIYMFYQKVGETSIDSWKNAGRVFKDSDKFDANDSILK
DQTQEWSGSATFTSDGKIRLFYTDFSGKHYGKQTLTTAQVNVSASDSSLNING
VEDYKSIFDGDGKTYQNVQQFIDEGNYSSGDNHTLRDPHYVEDKGHKYLVFE
ANTGTEDGYQGEESLFNKAYYGKSTSFFRQESQKLLQSDKKRTAELANGALG
MIELNDDYTLKKVMKPLIASNTVTDEIERANVFKMNGKWYLFTDSRGSKMTI
DGITSNDIYMLGYVSNSLTGPYKPLNKTGLVLKMDLDPNDVTFTYSHFAVPQ
AKGNNVVITSYMTNRGFYADKQSTFAPSFLLNIKGKKTSVVKDSILEQGQLTV
NK 
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5.10.2 Plasmid construction of Pduel 7 
Plasmid Pduel 7 was derived from pY+. The gene of GFP was replaced by 
gene of sacB. Using PYJ1712-SacB (Addgene) as template, sacB was amplified by 
two oligodeoxynucleotides (5’-
CCCCTCTAGATTTAAGAAGGAGATATACCATGAACATCAAAAAG-3’, and 5’-
CCGGCGAGCTCTTATTTGTTAACTGTTAA-3’), and then cloned into digested 
pY+ at two restriction sites Xba1 and Sac1 to make Pduel 7. 
5.10.3  The activity test of Pduel 7 
Pduel 7 was used together with the pBK-MmPylRS to transform E. coli Top10 
strain. For positive selection, the Top 10 cells were let grown on the LB plates, 12.5 
µg/mL of tetracycline and 25 µg/mL of kanamycin. 34 µg/mL or 68 µg/mL of 
chloramphenicol were used with and without 1 mM BocK. Without chloramphenicol, 
cells were healthy. In the presence of chloramphenicol, with 1 mM BocK, cells all 
survived; without BocK, cells all died. It indicated the positive selective marker 
function appropriately. For the negative, in the presence of sucrose, cells all died with 
and without BocK. 1% and 5% of sucrose both were enough to lead to cell death. 5% 
of glucose did not help (Table 8).  
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Table 8. Activity Test of Pduel 7 
 
Positive (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
34 or 68 µg/mL cm - + +   
1 mM BocK - - +   
 Grow Die Grow   
Negative (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
1% or 5% sucrose - + + + + 
5% Glucose - - - + + 
1 mM BocK - - + - + 
 Grow Die Die Die Die 
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5.11 Pduel 8: pRep-SacBK144TAG 
Since the control of T7 promoter is not very tight, we introduced one amber 
codon to SacB, to decrease the expression level of SacB (Figure 74).  
5.11.1 Plasmid construction of Pduel 8 
Plasmid Pduel 8 was derived from Pduel 7. The gene of SacB was replaced by 
gene of SacBK144TAG. Using Pduel 7 as template, SacBK144TAG was generated by 
site-directed mutagenesis using four oligodeoxynucleotides (5’-
CCCCTCTAGATTTAAGAAGGAGATATACCATGAACATCAAAAAG-3’, 5’-
GAATTTGTCGCTGTCCTAAAAGACGCGGCCAGC-3’, 5’-
GCTGGCCGCGTCTTTTAGGACAGCGACAAATTC-3’, and 5’-
CCGGCGAGCTCTTATTTGTTAACTGTTAA-3’), and then cloned into digested 
pY+ at two restriction sites Xba1 and Sac1 to make Pduel 8. 
5.11.2  The activity test of Pduel 8 
Pduel 8 was used together with the pBK-MmPylRS to transform E. coli Top10 
strain. For positive selection, the Top 10 cells were let grown on the LB plates, 12.5 
µg/mL of tetracycline and 25 µg/mL of kanamycin. 34 µg/mL or 68 µg/mL of 
chloramphenicol were used with and without 1 mM BocK. Without chloramphenicol, 
cells were healthy. In the presence of chloramphenicol, with 1 mM BocK, cells all 
survived; without BocK, cells all died. It indicated the positive selective marker 
function appropriately. For the negative, in the presence of sucrose, cells were all 
grown with and without BocK (Table 9). It indicated the mutation made SacB lose all 
activity. 
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Figure 74. Plasmid Structure of Pduel 8. 
 
 
Table 9. Activity Test of Pduel 8 
 
Positive (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
34 or 68 µg/mL cm - + + 
1 mM BocK - - + 
 Grow Die Grow 
Negative (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
5% sucrose - + + 
1 mM BocK - - + 
 Grow Grow Grow 
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5.12 Pduel 9: pRep-upp 
Since it’s very tricky to tune the activity of SacB, we moved to another 
negative selective marker, uracil phosphoribosyltransferase (uprt). Uprt coded by the 
gene of upp, converts 5-fluorouracil (5-FU) to 5-fluoro-dUMP, which inhibits 
thymidylate synthase, causing cell death. The new plasmid, Pduel 9 was obtained by 
replacing the gene of GFP in pY+ with the gene of upp (Figure 75). In the plasmid 
Pduel 9, for the negative selection, the upp gene, under control of T7 promoter, similar 
as Pduel 7, will be expressed by T7 polymerase, in the presence of 5-FU.  
 
 
 
 
Figure 75. Plasmid Structure of Pduel 9. 
 
 
Pduel 9
pDual9-upp
araC
T7-RNA Polymerase
GFPuv
uprt
CAT
TetR
araBAD
T7 promoter
T7 terminator
p15a ori
pylT
D112TAG
M1TAG
Q107TAG
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5.12.1 DNA and protein sequences of upp 
DNA sequence: 
5’-atgaagatcgtggaagtcaaacacccactcgtcaaacacaagctgggactgatgcgtgagcaagatatcagcaccaa 
gcgctttcgcgaactcgcttccgaagtgggtagcctgctgacttacgaagcgaccgccgacctcgaaacggaaaaagtaac
tatcgaaggctggaacggcccggtagaaatcgaccagatcaaaggtaagaaaattaccgttgtgccaattctgcgtgcggg
tcttggtatgatggacggtgtgctggaaaacgttccgagcgcgcgcatcagcgttgtcggtatgtaccgtaatgaagaaacg
ctggagccggtaccgtacttccagaaactggtttctaacatcgatgagcgtatggcgctgatcgttgacccaatgctggcaac
cggtggttccgttatcgcgaccatcgacctgctgaaaaaagcgggctgcagcagcatcaaagttctggtgctggtagctgc
gccagaaggtatcgctgcgctggaaaaagcgcacccggacgtcgaactgtataccgcatcgattgatcagggactgaacg
agcacggatacattattccgggcctcggcgatgccggtgacaaaatctttggtacgaaataa-3’ 
Protein sequence: 
MKIVEVKHPLVKHKLGLMREQDISTKRFRELASEVGSLLTYEATADLETEKVT
IEGWNGPVEIDQIKGKKITVVPILRAGLGMMDGVLENVPSARISVVGMYRNEE
TLEPVPYFQKLVSNIDERMALIVDPMLATGGSVIATIDLLKKAGCSSIKVLVLV
AAPEGIAALEKAHPDVELYTASIDQGLNEHGYIIPGLGDAGDKIFGTK 
5.12.2 Plasmid construction of Pduel 9 
Plasmid Pduel 9 was derived from pY+. The gene of upp was cloned into pY+, 
followed by GFP. The upp gene was amplified from the genomic DNA of E. coli 
Top10 strain by two oligodeoxynucleotides (5’-
TCCCTCTAGAGTGGCTGCCCCTCAAAGGAG-3’, and 5’-
TATTTCTAGATTATTTCGTACCAAAGATTTTGTC-3’), and then cloned into 
digested pY+ at two restriction sites Xba1 at both ends to make Pduel 9. 
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5.12.3  The activity test of Pduel 9 
The Top 10 cells transformed with Pduel 9 and pBK-MmPylRS were let grown 
on the LB plates, with 12.5 µg/mL of tetracycline and 25 µg/mL of kanamycin. The 
positive selective marker functioned very well. However, for negative conditions, with 
0.2% of arabinose, 1 mg/mL 5-FU, 1 mM Bock, the suppression was not obvious. 
Even when we changed to more sensitive GH371 E. coli whose genomic copy of upp 
was disrupted, the inhibition dynamic range was still restricted (Table 10).  
 
 
Table 10. Activity Test of Pduel 9 
 
Positive (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
68 µg/mL cm - + + 
1 mM BocK - - + 
 Grow Die Grow 
Negative (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
1mg/mL 5-FU - + + 
1 mM BocK - - + 
 Grow Grow Inhibition 
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5.13 Pduel 10: pRep-ccdB2m 
After using uprt, we tried one last negative selection marker, ccdB. CcdB, one 
part of ccd system of the F plasmid in E. coli, is responsible for the plasmid’s high 
stability by postsegregational killing of plasmid-free cells. The toxicity of the ccdB 
was demonstrated to reduce colony formation by more than five orders of magnitude 
and showed a great potential as an ideal negative selection marker. Thus, Pduel 10 was 
designed by replacing upp with ccdB2m in the Pduel 9 (Figure 76). CcdB2m, 
D44TAG and A13TAG, instead of ccdB, was chosen because of the high toxicity of 
ccdB. For the negative selection, the ccdB2m gene, under control of T7 promoter, will 
be produced and cause cell death in the presence of T7 polymerase. 
 
 
 
 
Figure 76. Plasmid Structure of Pduel 10. 
Pduel 10
10687 bp
araC
T7-RNA Polymerase
ccdBGFPuv
Cm(R)
Tet-R
araBAD
T7 Promoter
T7 terminator
p15a origin
pylt
Amber Asp112
M1 amber
Q107 amber
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5.13.1 DNA and protein sequences of ccdB 
DNA sequence: 
5’-atgcagtttaaggtttacacctataaaagagagagccgttatcgtctgtttgtggatgtacagagtgatattattgacacgc 
ccgggcgacggatggtgatccccctggccagtgcacgtctgctgtcagataaagtctcccgtgaactttacccggtggtgca
tatcggggatgaaagctggcgcatgatgaccaccgatatggccagtgtgccggtctccgttatcggggaagaagtggctga
tctcagccaccgcgaaaatgacatcaaaaacgccattaacctgatgttctggggaatataa-3’ 
Protein sequence: 
MQFKVYTYKRESRYRLFVDVQSDIIDTPGRRMVIPLASARLLSDKVSRELYPV
VHIGDESWRMMTTDMASVPVSVIGEEVADLSHRENDIKNAINLMFWGI 
5.13.2 Plasmid construction of Pduel 10 
Plasmid Pduel 10 was derived from pY+. The ccdB gene was amplified from 
pAraCB2 plasmid, which is a gift from Dr. Söll at Yale University by two 
oligodeoxynucleotides (TGTAGAGCTCTTATATTCCCCAGAACATCAGG, and 
TGTATCTAGATTATATTCCCCAGAACATCAGGTTAATGGCGTT), and then 
cloned into digested Pduel 9 by two restriction sites Xba1 at both ends to make Pduel 
10. 
5.13.3  The activity test of Pduel 10 
To demonstrate the applicability of the system, Top10/pRep-ccdB2m, pBK-
MmPylRS and Top10/pRep-ccdB1m, pBK-MmPylRS cells were prepared. Cell 
survival is highly NAA dependent (Figure 77). At positive condition, when 68 µg/mL 
of chloramphenicol were used, cells grew normally in media supplied with 1 mM 
BocK, but cell growth is suppressed in media without BocK. At negative conditions, 
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cell growth is suppressed in media supplied with BocK, but cells grew normally in 
media without BocK. Cells with pDual9-ccdB1m showed the same result under the 
negative conditions. However, cell growth is slightly suppressed at positive condition 
in the presence of BocK (Table 11). 
 
 
Table 11. Activity Test of Pduel 10 
 
Positive (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
 68 µg/mL cm - + + 
 1 mM BocK - - + 
ccdB1m  Grow Die Inhibition 
ccdB2m  Grow Die Grow 
Negative (LB) 
12.5 µg/mL tet 
25 µg/mL kan 
 0.2% arabinose - - + 
 1 mM BocK - + + 
ccdB1m  Grow Grow Die 
ccdB2m  Grow Grow Die 
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Figure 77. Demonstration of Pduel 10. The phenotype of Top10/pRep-ccdB2m, pBK-
MmPylRS, and Top10/pRep-ccdB1m, pBK-MmPylRS at positive A) negative 
conditions B). 
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5.14 Summary 
In summary, we have developed the one-plasmid selective system, which could 
carry out both the positive and negative library selection. This system could be applied 
to any library selection based on NAAs, and greatly simplified the selection process. 
Nowadays, more and more NAAs have been incorporated into proteins, and utilized to 
study proteins.  Our one-plasmid selection system will speed up the process of 
incorporation of NAAs, and therefore the understanding of protein functions. In the 
meantime, by generating a serial of one-plasmid system plasmids, we have thoroughly 
studied the positive and negative markers, and it’s helpful for us to optimize the 
selection process. 
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6. CONCLUSION  
 
Genetic incorporation of NAAs into proteins is a powerful approach to extend 
the diversity of amino acids. This method relies on the read-through of an in-frame 
amber (UAG) stop codon in mRNA by an amber suppressor tRNA (tRNACUA) 
specifically acylated with a NAA by an evolved aaRS. This system is equivalent to the 
naturally occurring pyrrolysine incorporation machinery discovered first in 
methanogenic archaea and a Gram positive bacterium Desulfitobacterium hafniense.59, 61, 
69, 141-143 In these organisms, Pyl is co-translationally inserted into proteins by an in-
frame amber codon. Similarly to the Pyl incorporation machinery, an orthogonal aaRS-
tRNACUA pair can be developed in which the aaRS is evolved to specifically charge its 
cognate tRNACUA with a NAA. When expressed in cells, this aaRS-tRNACUA pair 
enables a NAA to be site-specifically incorporated into a protein at the amber codon 
with high fidelity and efficiency. Using this approach, a variety of NAAs have been 
incorporated into proteins in bacteria, yeast and mammalian cells.84, 98, 116, 144-146  
PylRS/pylT, with unique features, demonstrates itself as the perfect tool to 
expand the genetic code. PylRS/pylT pair, which is orthogonal to the endogenous 
aaRS/tRNA pairs in both bacteria and eukaryotes, can be easily evolved in E. coli, and 
later transferred to eukaryotes. The large hydrophobic pocket in pylRS leads to notable 
substrate flexibility. Indeed, pylRS has been used to incorporate a variety of NAAs, from 
lysine analogs to tyrosine analogs (Figure 78). The lack of interaction between α-amino 
group and pylRS allows the incorporation of non-α-amino acid, which expands the 
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category of protein backbone. In addition, crystal structure revealed the missing direct 
interactions between the anticodon of pylT and pylRS. Taking advantage of all these 
unique features of pylRS/pylT pair, I have been able to carry out the following studies. 
 
 
 
 
 
 
Figure 78. Reprehensive NAAs taken by wtPylRS or its mutants. 
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6.1 Genetic incorporation of KetoK into one protein 
I demonstrated genetic incorporation of KetoK, an unhydrolysable analog of 
AcK for the installation of a permanent acetylation analog to proteins. Since KetoK has a 
keto group, it was also applied to achieve site-specific protein modification. KetoK 
synthesis followed the previous route with a 58% overall yield. The genetic encoding of 
KetoK by amber codon in E. coli was subsequently tested by transforming cells with 
pAcKRS-pylT-GFP1Amber and growing in media containing 2 mM KetoK. Since 
KetoK contains a keto group, we also tested the efficiency of using this group to 
specifically modify a protein incorporated with KetoK with hydrazine- and 
alkoxyamine-bearing compounds. To demonstrate the feasibility of using KetoK to 
perform protein fluorescent labeling, the purified GFP-KetoK was reacted with Texas 
Red hydrazine and biotin alkoxyamine at pH 6.3 for overnight. Both labeling gave high 
labelling specificity and efficiency (Figure 79). 
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Figure 79. Biotin alkoxyamine reaction with ketoK in GFPUV. 
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6.2 Genetic incorporation of multiple NAAs into one protein 
 I developed a novel strategy to incorporate multiple NAAs into one protein. The 
method is based on the decrease of the translation termination rate mediated by RF1. It 
has been suggested that the large ribosomal subunit protein L11 plays an important role 
in peptide release by RF1. By replacing L11 in ribosome with overexpressed L11C to 
enhance amber suppression, GFPUV with up to three AcKs has been expressed in E. coli.  
We first confirmed that overexpressing L11C enhances amber suppression. The results 
of protein expression in E. coli BL21 cells transformed with different plasmids and 
grown in different conditions are presented in Figure 80. The expression of GFP1Amber 
in the presence of overexpressed L11C was four times higher than that obtained in the 
absence of L11C. We then demonstrated that overexpressing L11C allows synthesizing 
proteins incorporated with multiple AcKs. GFP2Amber has amber mutations at positions 
149 and 204. GFP3Amber has one additional amber mutation at position 184.  
 
 
 
 
Figure 80. GFPUV expressed w/ and w/o L11C. 
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6.3 Genetic incorporation of two distinctive NAAs into a single protein  
I have developed a method to incorporate two distinctive NAAs into one protein 
in E. coli, which can be used to synthesize proteins with two different concomitant 
modifications. The method takes advantage of two aaRS-tRNACUA pairs evolved from E. 
coli (Figure 81). We attempted to combine the PylRS-pylT pair and the MjTyrRS-tRNA 
pair to incorporate two different NAAs into a single protein because of their proven 
efficiency in NAA incorporation.87, 100, 117, 118, 126-129 In order to use both pairs in a single 
E. coli cell, we first demonstrated that they are orthogonal to each other.  In order to 
demonstrate the utility of the PylRS-pylTUUA pair together with an evolved MjTyrRS-
tRNACUA pair to incorporate two different NAAs into a single protein in E. coli by both 
amber and ochre suppressions, two plasmids, pEVOL-AzFRS and pPylRS-pylT-
GFP1TAG149TAA, were used to transform E. coli BL21 cells. Full-length GFPUV were 
expressed when two corresponding NAAs were supplemented in media. Since 
GFPUV(2+4) contains both an alkyne group and an azide group, we tested the feasibility 
of separately labeling this protein with different fluorescent dyes by performing click 
reactions on these two functional groups. The labeling gave very high specify. 
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Figure 81. Strategy for two NAAs incorporation. 
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6.4 A straightforward one plasmid selection system for evolution of aaRSs 
I have developed an easy, straightforward selection method for the evolution of 
aaRSs in E. coli. This method relies on one plasmid, which is responsible for dual 
positive/negative selection. This plasmid utilizes an amber stop codon containing 
chloramphenicol acetyltransferase as positive selection marker, and two amber stop 
codon containing ccdB as negative selection marker. I demonstrated the utility of the 
system by identifying a variant of the MmpylRS from a library of 109 variants that 
selectively incorporates N-ε-carbobenzyloxy-lysine in response to an amber stop codon. 
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